Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  15-SEP-2016A Phase II, Double-Blind, Randomized, Multicenter Trial to 
Evaluate the Safety, Tolerability, and Immunogenicity of V114 
Compared to Prevnar 13™ in Healthy Infants
Product:   V114 1
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialTHIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION, NJ, U.S.A.
SPONSOR:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc. 
(hereafter referred to as the Sponsor or Merck)
One Merck Drive
P.O. Box 100
Whitehouse Station , New Jersey , 08889-0100, U.S.A.
Protocol -specific Sponsor Contact information can be found in the Investigator Trial File 
Binder (or equivalent) .
TITLE:
A Phase II, Double -Blind, Randomized, Multicenter 
Trial to Evaluate the Safet y, 
Tolerability , and Immunogenicity  of V114 Compared to Prevnar 13™ in Healthy  Infants
IND NUMBER:   14115
EudraCT NUMBER:   2016-001117-25 
  04HYHG 
  058TB6
Product:   V114 2
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialTABLE OF CONTENTS
SUMMARY OF CHANGES .................................................................................................. 9
1.0 TRIAL SUMMARY .................................................................................................. 10
2.0 TRIAL DESIGN ........................................................................................................ 11
Trial Design ........................................................................................................... 11 2.1
Trial Diagram ........................................................................................................ 12 2.2
3.0 OBJECTIVE(S) & HYPOTHESIS(ES) .................................................................. 12
Primary Objective(s) & Hypothesis(es) .............................................................. 12 3.1
Secondary Objective(s) & Hypothesis(es) ........................................................... 13 3.2
Exploratory Objective(s) ...................................................................................... 13 3.3
4.0 BACKGROUND & RATIONALE .......................................................................... 13
Background ........................................................................................................... 13 4.1
Pharmaceutical and Therapeutic Background .................................................... 14 4.1.1
Pre-clinical Trials ................................................................................................ 15 4.1.2
Clinical Trials ...................................................................................................... 15 4.1.3
Information on Other Trial -Related Therap y...................................................... 15 4.1.4
Rationale ................................................................................................................ 16 4.2
Rationale for the Trial and Selected Subject Population .................................... 16 4.2.1
Rationale for Dose Selection/Regimen ............................................................... 16 4.2.2
Rationale for the Use of Comparator ........................................................... 16 4.2.2.1
Rationale for Endpoints ...................................................................................... 16 4.2.3
Immunogenicit y Endpoints .......................................................................... 16 4.2.3.1
Safety  Endpoints .......................................................................................... 18 4.2.3.2
Future Biomedical Research ........................................................................ 19 4.2.3.3
Benefit/Risk ........................................................................................................... 19 4.3
5.0 METHODOLOGY ................................................................................................... 20
Entry Criteria ........................................................................................................ 20 5.1
Diagnosis/Condition for Entry  into the Trial ...................................................... 20 5.1.1
Subject I nclusion Criteria .................................................................................... 20 5.1.2 
  04HYHG 
  058TB6
Product:   V114 3
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialSubject Exclusion Criteria .................................................................................. 20 5.1.3
Trial Vaccination(s) .............................................................................................. 22 5.2
Dose Selection .................................................................................................... 22 5.2.1
Dose Selection (Preparation) ....................................................................... 22 5.2.1.1
Timing of Dose Administration .......................................................................... 23 5.2.2
Trial Blinding...................................................................................................... 23 5.2.3
Randomization or Vaccine Allocation ................................................................ 23 5.3
Stratification .......................................................................................................... 24 5.4
Concomitant Medications/Vaccinations (Allowed and Prohibited) ................. 24 5.5
Rescue Medications & Supportive Care ............................................................. 25 5.6
Diet/Activity/Other Considerations ..................................................................... 25 5.7
Subject Withdrawal/Discontinuation Criteria ................................................... 25 5.8
Discontinuation of Vaccination .......................................................................... 25 5.8.1
Withdrawal from the Trial .................................................................................. 26 5.8.2
Subject Replacement Strategy ............................................................................. 26 5.9
Beginning and End of the Trial ........................................................................... 26 5.10
Clinical Criteria for Early Trial Termination ................................................... 27 5.11
Subject Completion ............................................................................................... 27 5.12
6.0 TRIAL FLOW CHART ........................................................................................... 28
7.0 TRIAL PROCEDURES ........................................................................................... 30
Trial Procedures ................................................................................................... 30 7.1
Administrative Procedures .................................................................................. 30 7.1.1
Informed Consent ......................................................................................... 30 7.1.1.1
7.1.1.1.1 General Informed Consent .................................................................... 30
7.1.1.1.2 Consent and Collection of Specimens for Future Biomedical 
Research ................................................................................................ 31
Inclusion/Exclusion Criteria ........................................................................ 31 7.1.1.2
Subject I dentification Card .......................................................................... 31 7.1.1.3
Medical History ........................................................................................... 31 7.1.1.4
Prior and Concomitant Medications Review ............................................... 31 7.1.1.5
7.1.1.5.1 Prior Medications .................................................................................. 31
7.1.1.5.2 Concomitant Medications ..................................................................... 31 
  04HYHG 
  058TB6
Product:   V114 4
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialAssignment of Screening Number ............................................................... 32 7.1.1.6
Assignment of Treatment/Randomization Number ..................................... 32 7.1.1.7
Trial Compliance ......................................................................................... 32 7.1.1.8
7.1.1.8.1 Study  Vaccination ................................................................................. 32
7.1.1.8.2 Concomitant Vaccinations .................................................................... 33
Dispense Electronic Vaccination Report Cards ........................................... 34 7.1.1.9
Clinical Procedures/Assessments ........................................................................ 34 7.1.2
Physical Examinations ................................................................................. 34 7.1.2.1
Temperature ................................................................................................ .35 7.1.2.2
Assess Adverse Experiences ........................................................................ 35 7.1.2.3
Laboratory  Procedures/Assessments .................................................................. 35 7.1.3
Laboratory  Safet y Evaluations (Hematology, Chemistry  and Urinaly sis)..35 7.1.3.1
Blood Collection for Immunogenicit y Assa ys............................................. 36 7.1.3.2
Future Biomedical Research Samples ......................................................... 37 7.1.3.3
Other Procedures ................................................................................................ .38 7.1.4
Withdrawal/Discontinuation ........................................................................ 38 7.1.4.1
7.1.4.1.1 Withdrawal From Future Biomedical Research ................................... 38
7.1.4.1.2 Failure To Return For Scheduled Visits and/or Unable to Contact 
The Subject ........................................................................................... 38
Subject Blinding/Unblinding ....................................................................... 39 7.1.4.2
Domiciling ................................................................................................... 39 7.1.4.3
Calibration of Critical Equipment ................................................................ 40 7.1.4.4
Visit Requirements .............................................................................................. 40 7.1.5
Screening ...................................................................................................... 40 7.1.5.1
Vaccination Visits ........................................................................................ 40 7.1.5.2
Discontinued Subjects Continuing to be Monitored in the Trial ................. 40 7.1.5.3
Assessing and Recording Adverse Events .......................................................... 41 7.2
Definition of an Overdose for This Protocol and Reporting of Overdose to 7.2.1
the Sponsor .......................................................................................................... 41
Immediate Reporting of Adverse Events to the Sponsor .................................... 42 7.2.2
Serious Adverse Events ............................................................................... 42 7.2.2.1
Events of Clinical I nterest ............................................................................ 43 7.2.2.2
Evaluating Adverse E vents ................................................................................. 43 7.2.3 
  04HYHG 
  058TB6
Product:   V114 5
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialSponsor Responsibility  for Reporting Adverse Events ...................................... 46 7.2.4
TRIAL GOVERNANCE AND OVERSIGHT ................................................... 46 7.3
Executive Oversight Committee ......................................................................... 46 7.3.1
Data Monitoring Committee ............................................................................... 46 7.3.2
8.0 STATISTICAL ANALYSIS PLAN ........................................................................ 46
Statistical Analysis Plan Summary ..................................................................... 47 8.1
Responsibility for Analyses/In -House Blinding ................................................. 48 8.2
Hypotheses/Estimation ......................................................................................... 49 8.3
Analysis Endpoints ............................................................................................... 49 8.4
Immunogenicit y Endpoints ................................................................................. 49 8.4.1
Safety Anal ysis Endpoints .................................................................................. 50 8.4.2
Analysis Populations ............................................................................................. 50 8.5
Immunogenicit y Analysis Populations ............................................................... 50 8.5.1
Safety Anal ysis Populations ............................................................................... 50 8.5.2
Statistical Methods ................................................................................................ 50 8.6
Statistical Methods for Immunogenicit y Anal yses............................................. 50 8.6.1
Statistical Methods for Safety Anal yses............................................................. 52 8.6.2
Summaries of Demographics and Baseline Characteristics ................................ 53 8.6.3
Interim Analyses ................................................................................................... 53 8.7
Multiplicity ............................................................................................................ 54 8.8
Sample Size and Power Calculations .................................................................. 55 8.9
Immunogenicit y Analyses .................................................................................. 55 8.9.1
Safety Anal yses................................................................................................... 56 8.9.2
Subgroup Analyses and Effect of Baseline Factors ........................................... 57 8.10
Extent of Exposure ................................................................................................ 57 8.11
9.0 LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES ................................................................................................................. 57
Investigational Product ........................................................................................ 57 9.1
Packaging and Labeling Information ................................................................ .58 9.2
Clinical Supplies Disclosure ................................................................................. 58 9.3
Storage and Handling Requirements .................................................................. 58 9.4
Discard/Destruction/Returns and Reconciliation .............................................. 58 9.5 
  04HYHG 
  058TB6
Product:   V114 6
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialStandard Policies ................................................................................................... 59 9.6
10.0 ADMINISTRATIVE AND REGULATORY DETAILS ....................................... 59
Confidentiality ....................................................................................................... 59 10.1
Confidentiality  of Data ....................................................................................... 59 10.1.1
Confidentiality  of Subject Records ..................................................................... 59 10.1.2
Confidentiality  of Investigator Information ........................................................ 59 10.1.3
Confidentiality  of IRB/IEC I nformation ............................................................. 60 10.1.4
Compliance with Financial Disclosure Requirements ....................................... 60 10.2
Compliance with Law, Audit and Debarment ................................................... 60 10.3
Compliance with Trial Registration and Results Posting Requirements ........ 62 10.4
Quality Management System ............................................................................... 63 10.5
Data Management ................................................................................................ .63 10.6
Publications ........................................................................................................... 63 10.7
11.0 LIST OF REFERENCES ......................................................................................... 65
12.0 APPENDICES ........................................................................................................... 67
Merck Code of Conduct for Clinical Trials ........................................................ 67 12.1
Collection and Management of Specimens for Future Biomedical 12.2
Research ................................................................................................................. 69
Approximate Blood/Tissue Volumes Drawn/Collected by Trial Visit and 12.3
by Sample Types ................................................................................................... 73
List of Abbreviations ............................................................................................ 74 12.4
13.0 SIGNATURES ........................................................................................................... 76
Sponsor's Representative ..................................................................................... 76 13.1
Investigator ............................................................................................................ 76 13.2 
  04HYHG 
  058TB6
Product:   V114 7
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialLIST OF TABLES
    
Table 1  Trial Vaccinations..................................................................................................... 22
Table 2  Evaluating Adverse Events ....................................................................................... 44
Table 3  Anal ysis Strategy  for Immunogenicit y Variables ..................................................... 51
Table 4
  Anal ysis Strategy  for Safet y Parameters .................................................................. 53
Table 5  Summary  of Interim Anal ysis Strategy .................................................................... 54
Table 6  Assumptions of the True Response Rates for V114 and Prevnar 13™ for the 13 
Common Seroty pes..................................................................................................... 56
Table 7  Difference s in Incidence of Adverse event Rates between the Two Vaccination 
Groups That Can be Detected With an ~80% Probability  and a Two-Sided 
Significance Level of 0.05 .......................................................................................... 57
Table 8  Product Descriptions ................................................................................................. 57 
  04HYHG 
  058TB6
Product:   V114 8
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialLIST OF FIGURES
         
Figure 1   Trial Design ................................ ................................ ................................ ............. 12
Figure 2   Diagram of the Multiplicity  Adjustment ................................ ................................ .54 
  04HYHG 
  058TB6
Product:   V114 9
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON (S) FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
4.2.3. 3 Exploratory  B iomarker 
ResearchSection 4.2.3.2 Exploratory  
Biomarker Research was 
removed . This section was removed as it 
is not applicable to this study .
This section was inadvertently  
included in the initial protocol.
ADDITIONAL CHANGE (S)FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
4.2.3.1
7.1.1.8.2
7.1.3.2
7.1.3.3Immunogenicit y Endpoints
Concomitant Vaccinations
Blood collection for 
Immunogenicit y Assa ys
Future Biomedical Research 
Samples#3 and #4 were removed 
The following sentence was 
added: “Combination MMRV 
vaccines should not be given in 
this study ; however, MMR and 
Varicella vaccines are 
permitted if 
administered 
concomitantly  in 2 separate 
limbs.”
“pneumo- specific” was added 
and “to all 15 vaccine seroty pes 
included in V114 ” was 
removed.   
”which would routinely  be 
discarded after the main study  
is over” was re moved. They  a re not trial 
immunogenicit y endpoints
Statement was inadvertently  
left out of previous version of 
the protocol.
To ensure that all necessary 
seroty pes will  be tested
Incorrect sentence in the 
context of V114 development.  
No additional changes. 
  04HYHG 
  058TB6
Product:   V114 10
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential1.0TRIAL SUMMARY
Abbreviated Title Safety/Immunogenicity of Different Lots of V114 vs. Prevnar 13™
in Infants
Sponsor Product Identifiers V114
Generic name not yet assigned
Trial Phase II
Clinical Indication Prevention of pneumococcal disease
Trial Type Interventional
Type of control Active control without placebo
Route of administration Intramuscular
Trial Blinding Double -blind
Vaccination Groups Subjects will be randomly assigne d to receive V114 Lot 1, V114 
Lot 2, or Prevnar 13™ (control). See Section 5.2for a detailed 
description of the V114 lots ).
Number of trial subjects Approx imately 1,050 subjects will be enrolled.
Estimated duration of trial The Sponsor estimates that the trial will require approximately 2 
years from the time that written informed consent is provided for 
the first subject until the last subject’s last study -related phone call 
or visit.   For purposes of analysis and reporting, the overall trial 
ends when the Sponsor receives the last serolog icalresult s.
Duration of Participation Each subject will participate in the trial for approximately 11 to 14 
months from the time the parent/legal guardian signs the informed 
consent form (ICF)through the final contact.  Each subject will 
receive 4 doses of the trial vaccine given at approximately 2, 4, 6, 
and 12 to 15 months of age.  After each vaccination, the trial subject 
will be observed for 30 minutes and follow ed for 14 days for 
injection site and systemic adverse events (AEs).  Serious adverse 
events (SAEs) will be collected from the time the consent form is 
signed through 30 days post-dose 4 (PD4) and/or completion of the 
subject’s participation in the trial, see Section 7.2 for details .  Blood 
samples will be collected 1 monthfollowing dose 3, immediately 
prior to dose 4, and 1 month follow ing dose 4.
A list of abbreviations used in this document can be found in Section 12.4.Randomization Ratio 1:1:1 
  04HYHG 
  058TB6
Product:   V114 11
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential2.0TRIAL DESIGN
Trial Design 2.1
This is a multice nter, randomized, double -blind trial to evaluate the safety , tolerability , and 
immunogenicit y of 2 different lots of V114 in health y infants to be conducted in 
conformance with Good Clinical Practices (GCPs) .  Prevnar 13™ (pneumococcal 13-valent 
conjugate vaccine [diphtheria CRM 197protein] , Wyeth Pharmaceuticals, Inc., Philadelphia, 
Pa) will serve as the active control.  This trial will enroll approximately  1,050 healthy  infants 
6 to 12 weeks ( ≥42 to ≤90 day s) of age.  Subjects will be randomly  assigned to receive V114 
Lot 1(n=350), V114 Lot 2(n=350) or Prevnar 13™ (n=350). (See Section 5.2 for a detailed 
description of the V114 lots).
A 0.5mL  intramuscular dose of the trial vaccine will be administered to healthy  infants at 
approximately  2, 4, 6, and 12 to 15 months of age. 
The safet y and tolerability  profile of V114 will be carefully  monitored throughout the trialby 
both the SPONSOR in accordance with standard procedures and by an external Data 
Monitoring Committee (eDMC ). (Details regarding in-house blinding of SPONSOR 
personnel can be found in Section 5.2.3 . ‘Trial Blinding’).
Any trial subject with a serotype -specific anti -pneu mococcal immunoglobulin G ( IgG)value , 
as measured by pneumococcal electrochemiluminescence (PnECL )assay below 0.35 μg/mL  
for serot ype 19A (individually ) or below 0.35 μg/mL  for 4 or more of the other serot ypes in 
comm on with Prevnar 13™ at 1 month post-dose 3 (PD3) will be discontinued from the 
study  and offered an additional dose of licensed pneumococcal conjugate vaccine outside of 
this protocol . See Section 5.6 (Rescue Medications & Supportive Care )for additional details 
of the rescue plan.
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial Flow Chart -Section 6.0. Details of each 
procedure are provided in Section 7 .0–Trial Procedures. 
  04HYHG 
  058TB6
Product:   V114 12
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialTrial Diagram 2.2
The trial design is shown inFigure 1.
†Refer to Protocol Section 6.0 Trial Flow Chart for acceptable age ranges and/or visit windows
Figure 1  Trial Design
3.0OBJECTIVE(S) & HYPOT HESIS(ES)
Primary Objective(s) & Hypothesis (es) 3.1
In healthy  infants receiving one of the 2V114 lotsor Prevnar 13™ at approximately  2, 4, 6, 
and 12- 15 months of age:
1.Objective: To describe the safet y and tolerability profiles of 2 different lotsof V114 
[Lot 1(V114 -1), Lot 2 (V114 -2)], after each dose .
 
  04HYHG 
  058TB6
Product:   V114 13
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential2.Objective: To demonstrate that V114 (either V114 -1 or V114 -2)is non-inferior to 
Prevnar 13™for the 13 shared serot ypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 
19F, and 23F), based on the proportion of subjects meeting serot ype-specific 
immunoglobulin G (IgG) threshold value of ≥0.35 µg/mL at 1 month post-dose 3 
(PD3 ).
Hypothesis: The proportion of subjects receiving V114 (either V114 -1 or V114 -2) 
who have seroty pe specific IgG ≥0.35 µg/mL , as measured by the Pn ECL assay , for 
each of pneumococcal seroty pes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F,and 
23F at 1 month PD3 is non -inferior to that for recipients of Prevnar 13™.
[The statistical criterion for non-inferiority  corresponds to the lower bound of the 
adjusted 95% CI of the proportion difference (V114 minus Prevnar 13™) being 
greater than -0.15 for each of the 13 shared serotypes. ]
3.Objective: Toevaluate the serot ype-specific IgG geometric mean concentrations 
(GMCs) of V114 -1, V114 -2, and Prevnar 13™, and the IgG GMC ratios between 
each of the two V114 lotsand Prevnar 13™ for all 15 seroty pes included in V114 (1, 
3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) at 1 month PD3.
Secondary Objective(s) & Hyp othesis(es) 3.2
1.Objective: Toevaluate the serot ype-specific IgG GMCs of V114 -1, V114 -2, and 
Prevnar 13™, and the IgG GMC ratios between each of the two V114 lots and 
Prevnar 13™ for all 15 seroty pes included in V114 at pre-dose 4 and 1 month post-
dose 4 (PD4).
Exploratory Objective(s) 3.3
1.To evaluate the seroty pe-specific IgG response rates of V114 -1, V114 -2, and Prevnar 
13™, and the differences in IgG response rates between each of the two V114 lots 
and Prevnar 13™ for the 2 seroty pes unique to V114 (22F and 33F) at 1 month PD3
and all 15 serot ypes included in V114 at pre-dose 4 and 1 month PD4. The serot ype-
specific IgG response rate will be based on the proportion of subjects achieving 
seroty pe-specific IgG ≥0.35 µg/mL as measured by  the Pn ECL assay .
2.To describe the proportions of subjects with opsonophagocy tic killing activity (OPA )
titer ≥8 and OPA geometric mean titers (GMTs) as measured by MOPA -4 assay in 
subjects receiving V114 -1,V114 -2, and Prevnar 13™ for all 15 seroty pes included in 
V114 at 1 month PD3, pre -dose 4, and 1 month PD4.
4.0BACKGROUND & RATIONA LE
Background 4.1
Refer to t he Investigator’s Brochure (IB) for detailed background information on V114 . 
  04HYHG 
  058TB6
Product:   V114 14
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialPharmaceutical and Therapeutic Background 4.1.1
The investigational Merck pneumococcal conjugate vaccine , hereafter referred to as V114 , is 
a 15-valent conjugate vaccine that contains all 13pneumococcal seroty pes contained in 
Prevnar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 23F), and 2 additional 
pneumococcal seroty pes (22F, 33F).  The pneumococcal serot ypes contained in V114 will 
provide broad er covera ge of the current leading serot ypes associated with pneumococcal 
disease worldwide.  The vaccine is designed to meet continuing medical and public health 
global needs for pneumococcal conjugate vaccines  as well as to address the emergence of 
pneumococcal disease caused by  seroty pes not contained in currently  licensed pneumococcal 
conjugate vaccines.   The pneumococcal serot ype composition of V114 isbased on the need 
to maintain coverage of the serot ypes included in Prevnar 13™, and to add seroty pes guided 
by current epidemiology  data and emerging trends [1].
Streptococcus pneumoniae (pneumococcus) is a major worldwide cause of morbidity  and 
mortality and isresponsible for more than half of all community- acquired pneumonia (CAP), 
otitis media, bacteremia and meningitis cases [2]. Bacteremia and meningitis are referred to 
as invasive pneumococcal disease (IPD). In 2006, the World Health Organization (WHO) 
estimated that pneumococcus causedthe deaths of at least 1.5 million people annuall y [2]. In 
2009, pneumococcus accounted for over 1 million deaths in children <5 years of age, mostl y 
in developing countries [3, 4].  
Three licensed pneumococcal conjugate vaccines have been licensed since 2000 . The 7-
valent Prevnar™ , conjugated to diphtheria toxoid mutant (PCV7 -CRM 197)was first licensed 
and introduced into national childhood vaccination schedules in the US, European Union 
(EU), and several other countries. Since then , a 10 -valent (PCV10), and a 13 -valent (PCV13 -
CRM 197) pneumococcal conjugate vaccine have also been licensed .  PCV13 -CRM197 was 
approved in the EU in 2009, the US in 2010, and subsequently  in other countries worldwide.  
The vaccine is licensed globally  as Prevnar 13™ and Prevenar 13™, and in this protocol the 
vaccine will be referred to by the name Prevnar 13™.  In 2009 PCV10 marketed as 
Synflorix™ (pneumococcal 10-valent conjugate vaccine [Non -Typeable Haemophilus 
influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates], GlaxoSmithKline 
Biologicals s.a., Rixensart, Belgium) was licensed in Europe and other countries worldwide.  
Synflorix™ contains the seroty pes contained in Prevnar™ conjugated to 3 different carrier 
proteins, plus 3 additional capsular polysaccharide conjugates (serot ypes 1, 5, and 7F).  This 
vaccine is currentl y not licensed in the US. According to the US pediatric vaccination 
schedule, licensed PCV is administered to infants in a 3-dose infant primary  series (at 
approximately  2, 4, and 6 month s of age), followed by  a toddler (fourth) dose at age 12 to 15 
months of age .  
  04HYHG 
  058TB6
Product:   V114 15
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialPCV7 was highl y effective in preventing invasive pneumococc al dise ase (IPD) caused by  the 
seroty pes included in the vaccine in children targeted for the vaccine [5], in providing 
moderate protection against pneumococcal acute otitis media (AOM) [6]and pneumonia [7]. 
Widespread use of PCV7 also decreased transmission of pneumococcal disease caused by 
vaccine serot ypes in individuals not targeted by the vaccination program [8, 9]. PCV10 and 
PCV13 were licensed on the basis of immunogenicity  and reactogenicity  profiles comparable 
with that of PCV7 . Despite the above mentioned public health benefits of PCV7 [10], 
seroty pe replacement emerged as an important public health conc ern as new serot ypes begin 
to fill the niche created by the suppression of nasophary ngeal colonization of vaccine 
seroty pes [1 1].  In the US, serot ype19A was, for instance, a leading causative pneumococcal 
seroty pe of IPD and respiratory  disease several years ago [12, 13]. More recently , IPD cases 
caused by seroty pes 22F and 33F, the 2 additional serot ypes contained in V114 (not 
contained in Prevnar 13™) have also increased. Although only contributing for  1.2% of all 
IPD cases in US children under 5 yearsof age in 1998 -1999 [14], IPD caused by these 2 
seroty pes increased to approximately  9.6% and 29% of IPD cases by 2006-2007 and 2011, 
respectivel y [15].  This phenomenon of serot ype replacement substantiates the need for the 
development of more broadly -based pneumococcal conjugate vaccines.
Pre-clinical Trials 4.1.2
Preclinical immunogenicity  studies of V114 formulations have been conducted in 2 animal 
models (refer to the V114 IB).
Clinical Trials 4.1.3
Several clinical trials of a single dose (toddlers, young and older adults) and 4 -dose series 
(infants) of V114 have been conducted to evaluate the safet y and immunogenicity  of various 
formulations of V114 containing different amounts of pneumococcal polysaccharide and 
aluminum adjuvant. Trial results showed that V114 display s an acceptable safety  profile and 
induces serot ype-specific antibodies (IgG and OPA) to all 15seroty pes included in the 
vaccine (See IB for additional information).
Information on Oth er Trial -Related Therapy 4.1.4
In this trial, Prevnar 13™ will be administered as one of the trial vaccines, to serve as the 
active comparator.  In addition to the administration of trial vaccine (V114 or Prevnar 13™), 
other pediatric vaccines will be administer ed concomitantly  according to the recommended 
schedule for sites in the United States and according to local, regional, and/or country 
guidelines outside of the United States .  
  04HYHG 
  058TB6
Product:   V114 16
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialRationale 4.2
Rationale for the Trial and Selected Subject Population 4.2.1
Safety  and immunogenicity  of several formulations of V114 containing different 
concentrations of pneumococcal capsular polysaccharide and aluminum adjuvant were 
evaluated in small Phase I/IIclinical trials involving a small number of adults and infants. 
The leading formulation display ing acceptable safety  profile and optimal immune responses 
in these studies will be evaluated in a larger number of infants in V114 -008. This trial is 
designed to select the optimal quality  attributes of the vaccine contained in either V114 lot to 
be tested in subsequent phases of V114 clinical development .The trial will enroll healthy 
infants at approximately  2 months of age, consistent with current recommendation of routine 
vaccinati on with PCV in earl y childhood .
Rationale for Dose Selection/Regimen   4.2.2
 
 
 
 
 
 
Rationale for the Use of Comparator 4.2.2.1
Placebo -controlled clinical studies, for new PCVs, are no longer feasible given the proven 
clinical efficacy  and widespread use of licensed pneumococcal conjugate vaccine worldwide .  
Prevnar 13™ is cu rrently the only recommended vaccine for the prevention of pneumococcal 
disease in infants in the US and is also used in many  other countries worldwide. It will be 
used as the active comparator in this trial.
Rationale for Endpoints 4.2.3
Immun ogenicity Endp oints 4.2.3.1
Serum will be collected at 3 pre -specified time points during the trial:
1)Approximately  1 month PD3
2)Pre-dose 4
3)Approximately  1 month PD4
Sera will be used for the following measurements:
(1)IgG responses using the Pn ECL  assay .
(2)Functional antibod y activi ty, OPA, will be measured using the MOPA -4 assay  in the 
first 50% of infant subjects enrolled at US investigator sites who have sufficient 
serum volume at PD3 to perform both the PnECL and MOPA -4 assay s.OPA will be 
conducted at Pre-Dose 4 and PD4for all of the subjects who had OPA performed at 
PD3 and for which there is sufficient volume. 
  04HYHG
CCI 
  058TB6
Product:   V114 17
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialThere are two primary immunogenicit y endpoints in this trial: 
(1)The serot ype- specific IgG responses (proportion of responders achieving IgG 
reference level of ≥0.35 μg/mL) induced by V114 -1, V114 -2, and Prevnar 13™, by 
Pn ECL  assay at 1 month following receipt of the third dose of the trial vaccine for 
the 13 serot ypes s hared with Prevnar 13™
.
The use of the ≥0.35 μg/mL threshold value has been recommended as an acceptable 
threshold value for evaluating the clinical performance of pneumococcal conjugate 
vaccines [16], [17].
(2)The IgG GMCs for all 15 seroty pes included in 
V114 at 1 month post -dose 3.
Other immunoge nicity  endpoints include:
(1)The serot ype-specific responses for V114- 1, V114 -2, and Prevnar 13™, based on IgG 
GMCs by Pn ECL assay immediatel y prior (pre-dose 4) and 1 month following 
receipt of the fourth dose of t he study  vaccine for all 15 seroty pes included in V114.
(2)The serot ype-specific responses for V114 -1, V114 -2, and Prevnar 13™, based on the 
proportion of subjects meeting the serot ype-specific threshold value of ≥0.35 μg/mL 
by Pn ECL  assay at 1 month followi ng receipt of the third dose of the study  vaccine 
for the two seroty pes unique to V114, and immediately prior (pre-dose 4) and 1 
month following receipt of the fourth dose of the study  vaccine for all 15 serot ypes 
included in V114 .
Functional antibody  activity, OPA, will also be evaluated in approximately 50% ofinfants 
enrolled at US study sites with suffici entserum a vailable at PD3 to perform both the Pn ECL 
assay  and the OPA testing on all 15 seroty pes in V114.  Pre-dose 4 and PD4 OPA 
measurements will be conducted for all of the subjects who had PD3 OPAs performed and 
for which there is sufficient serum.  The proportion of subjects meeting OPA titer ≥8 and the 
OPA GMTs at PD3 and separately  at pre-dose 4 and PD4 will be summarized for each 
seroty pe.
Primary  immunogenicity endpoints for the comparison of pneumococcal conjugate vaccines 
in children are based on immunoglobulin (IgG) antibodies responses. Such responses are 
consistent with the recommendations from the World Health Organization (WHO) and many 
regulatory  agencies worldwide and include serot ype-specific measurements of the following 
endpoints : a) the proportion of subjects achieving IgG antibody  concentrations ≥0.35 μg/mL  
four weeks after third dose; and b) the IgG geometric mean antibody  concentration (GMC) 
measured 4 weeks after the third and fourth dose s. For new serot ypes notincluded in licensed 
pneumococcal conjugate vaccine used as comparator , non- inferiority  comparison sare made 
to the lowest response rate observed to any  vaccine se rotype among recipients of the licensed 
vaccine .  
  04HYHG 
  058TB6
Product:   V114 18
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialSafety Endpoints 4.2.3.2
Adverse event s (AEs) will be documented on a validated vaccination report card (VRC).  
The VRC was developed to be administered electronically  via a hand -held device.  All AEs 
will be assessed for intensity .
1.Trial subjects will be observed for 30 minutes postvaccination for any immediate 
AEs.
2.Solicited injection -site AEs (redness, swelling, hard lump, and pain/tenderness) and 
solicited systemic AEs (irritability , drowsiness, hives/welt s, and appetite lost) will be 
collected Day  1 to Day  14 after each vaccination.
3.Any other unsolicited systemic or injection -site AEs will be collected Day 1 to Day 
14 after each vaccination.
4.Serious AEs will be collected from the time the consent form is signed through 30 
days PD4 and/or completion of the subject’s participation in the trial.  Refer to 
Section 7.2.2.1 for complete detail on serious AE data collection.
5.Body temperature will be measured during Day 1 to Day 7 after each vaccination.  If 
fever is suspected, temperature will also be measured during Day 8  to Day 14 
postvaccination.
The 14-day safet y follow -up period for AEs occurring following receipt of each dose of the 
trial vaccine is consistent with other clinical trials evaluating the safet y of licensed 
pneumococcal conjugate vaccines in healthy infants.
Safety Monitoring
Safety  and tolerability  profiles will be carefully monitored throughout the trial by the 
SPONSOR in accordance with standard procedures and also by an external Data Monitorin g 
Committee (eDMC ).  Please see Section 7.3.2 Data Monitoring Committee for details 
regarding the composition, roles and responsibilites of the eDMC .
In order to evaluate the safet y profile of V114 in infants, VRC -prompted injection -site 
adverse event s (redness, swelling, hard lump [rated by size] and pain/tenderness) and VRC -
prompted systemic adverse event s (irritability , drowsiness, appet ite lost, hives/ welts) will be
recorded for 14 day s.  If a hard lump at the injection site is present for 72 hour s, the subject's 
parent/legal guardian should immediately  contact the site to schedule an appointment with 
the trial site for an evaluation within 48 hours, where the trial doctor will diagnose the 
injection -site reaction (e.g., induration or nodule).  If hives/welts (urticaria) occur, the 
subject's parent/legal guardian should immediately  contact the site to schedule an 
appointment with the trial site for an evaluation within 48 hours, where the trial doctor will 
determine whether the hives/welts represent an urticarial -like eruption.  Unsolicited systemic 
or injection -site adverse event s or serious adverse event s will be collected from Day 1 
through Day 14 after each vaccination. Serious adverse events (regardless of the 
investigator's assessment of causa lity) from the time the consent form is signed through 
completion of the subject's participation in the trial at 30 days after the last dose of trial 
vaccine will be collected (see Section 7.2for details).   Any immediate adverse event s 
occurring in the 30minutes postvaccination observation period will be recorded.  
Information about any medications, including any analgesic/antipy retic use on the day of  
  04HYHG 
  058TB6
Product:   V114 19
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidentialvaccination that the subject receives, should be documented throughout the trial on the VRC 
for the 14 -day safety  follow -up period following each vaccination. 
Future Biomedical Research 4.2.3.3
 
 
 
 
 
 
 
 
 
 
 
Benefit/Risk 4.3
Subjects in clinical trials generally  cannot expect to receive direct benefit from vaccination 
during participation, as clinical trials are designed to provide information about the safety 
and efficacy of an investigationa l medicine.
A subset of subjects will receive Prevnar 13™ which is the standard of care and is serving as 
the active comparator in this trial. V114 is aimed at providing comparable immune 
responses to Prevnar 13™ for the shared serotypes while providing additional coverage for 
the 2 seroty pes (22F and 33F) unique to V114.  It is unknown if the investigational V114 will 
have the same benefit as Prevnar 13™. As a possible rescue medication in this trial, subjects 
who fail to achieve adequate immune response s to seroty pe 19A (individually ) or to 4 or 
more other serot ypes in common between Prevnar 13™ and V114 following the third dose of 
trial vaccine will be offered an additional dose of licensed pneumococcal conjugate vaccine 
as soon as possible after serolo gy results are available . (See Section 5.6 Rescue Medications 
& Supportive Care for additional details ).
Additional details regarding specific benefits and risks for subjects participating in this 
clinical trial may be found in the accompanying Investigato rs Brochure (IB) and Informed 
Consent documents. 
  04HYHG
CCI 
  058TB6
Product:   V114 20
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential5.0METHODOLOGY
Entry Criteria 5.1
Diagnosis/Condition for Entry into the Trial 5.1.1
Health y male and female infants approximately  2 months of age(between 42 and 90 days 
old)(inclusive) will be enrolled in this trial.
Subject Inclusion Criteria 5.1.2
In order to be eligible for participation in this trial, the subject must:
1.Be healthy  (based on medical history  and phy sical examination) male or female infant 
approximately  2 months of age (42 day s to 90 days), inclusive.
2.Have aparent/legal guardian who understands the trial procedures, alternate 
treatments available, and risks involved with the trial.
3.Have a parent/legal guardian who is able to read, understand, and complete the VRC
and voluntarily  agree to participate by  givin g written informed consent .
4.Aparent/legal guardian also acknowledges that they :
a.willattend all scheduled visits
b.comply  with the trial procedures , and 
c.have access to a telephone.
Subject Exclusion Criteria 5.1.3
The subject must be excluded from participating in the trial if the subject:
If the subject meets criteria marked with an asterisk (*), the Day 1 Visit may be 
rescheduled for a time when these criteria are not met.
1.Had prior administration of an y pneumococcal vaccine.
2.Has a known hypersensitivity  to anycomponent of the pneumococcal conjugate 
vaccine, or an y diphtheria toxoid -containing vaccine.
3.*Had a recent febrile illness (rectal temperature ≥38.1°C [≥100.5°F] or axillary  
temperature ≥37.8°C [≥100.0°F]) occurring within 72 hours prior toreceipt of trial
vaccine.
4.Has a known or suspected impairment of immunological function.
5.Has a history  of congenital or acquired immunodeficiency  (e.g. splenomegaly ).
6.Has or his/her mother has a documented human immunodeficiency  virus (HIV) 
infection.
7.Has or his/her mother has a documented hepatitis B surface antigen –positive test. 
8.Has known or history  of functional or anatomic asplenia.
9.Has a history  of failure to thrive. 
  04HYHG 
  058TB6
Product:   V114 21
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential10.Has known or history of a coagulation disorder contraindicating intramuscular 
vaccination.
11.Has a history  of autoimmune disease including systemic lupus erythematosus, anti-
phospholipid syndrome, Behcet's disease, autoimmune thyroid disease, polymyositis 
and dermatomy ositis, scleroderma, type 1diabetes mellitus, and other autoimmune 
disorders.
12.Has a known neurologic or cognitive behavioral disorder, including 
encephalitis/my elitis, acute disseminating encephalomy elitis, pervasive development 
disorder, and related disorders.
13.*Meets one or more of the following s ystemic corticosteroid exclusion crite ria:
Has received sy stemic corticosteroids (eq uivalent of ≥2 mg /kg tot al daily dose of 
prednisone or ≥20 mg/d forpersons weighing > 10 kg) for ≥
14 consecutive day s 
and has not completed this course of treatment at least 30 days prior to trial 
randomization.  
Has received systemic corticosteroids within 14 days prior to the first dose of 
vaccine at randomization.
Is expected to require systemic corticosteroids within 30 days after each 
vaccination during conduct of the trial. .
14.*Has receiv ed other licensed non-live vaccines within the 14 days before receipt of 
first dose of trial vaccine.   
15.*Has received a licensed live virus vaccine within the 30 days prior toreceipt of first 
dose of trialvaccine.
16.Had prior receipt of a blood transfusion or blood products, including 
immunoglobulins.
17.Has participated in another clinical trial of an investigational product before the 
beginning or anytime during the duration of the current clinical trial
. Subjects 
enrolled in observational studies may be included; these will be reviewed on a case-
by-case basis for approval by the SPONSOR.
18.Has a history  of invasive pneumococcal disease (positive blood culture, positive 
cerebrospinal fluid culture, or other sterile site) or known history  of other culture 
positi ve pneumococcal disease.
19.Cannot be adequately  followed for safet y according to the protocol plan.
20.Has a parent/legal guardian who is unlikely  to adhere to trial procedures, keep 
appointments, or is planning to relocate during the trial.
21.Has any other reason that in the opinion of the investigator may interfere with the 
evaluation required b y the trial.
22. Is or has an immediate family  member (e.g., spouse ,parent/ legal guardian , sibling or 
child) who is investigational site or sponsor s taff directly  involved with this trial. 
  04HYHG 
  058TB6
Product:   V114 22
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialTrial Vaccination(s) 5.2
The v accine s to be used i n this trial are outlined below in Table 1.
Table 1  Trial Vaccination s
Trial
VaccinesDose/
PotencyDose 
FrequencyRoute of 
AdministrationRegimen/ 
Vaccination PeriodUse
V114 -1
(Lot 1 )0.5 mL 1 Intramuscular 
injection1Each subject will 
receive 4 doses of 
the trial vaccine 
given at 
approximately 2, 4, 
6, and 12 to 15 
months of age.Investiga tional 
V114 -2
(Lot 2 )0.5 mL 1 Intramuscular 
injection1Each subject will 
receive 4 doses of 
the trial vaccine 
given at 
approximately 2, 4, 
6, and 12 to 15 
months of age.Investiga tional 
Prevnar 
13™0.5 mL 1 Intramuscular 
injection1Each subject will 
receive 4 doses of 
the trial vaccine 
given at 
approximately 2, 4, 
6, and 12 to 15 
months of age.Active 
Comparator
1Each trialvaccine is to be injected into the deltoid muscle of the upper arm .
Trial vaccination (first dose of trial vaccine )will be given on the day of treatment 
allocation/ randomization or as close as possible to the date on which the subject is 
allocated/assigned.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribu tion and usage of trial 
treatments in accordance with the protocol and an y applicable laws and regulations.
Dose Selection 5.2.1
Dose Selection (Preparation) 5.2.1.1
The rationale for selection of doses to be used in this trial is provided in Section 4.0 –
Background & Rationale.  There are no specific calculations or evaluations required to be 
performed in order to administer the proper dose to each subject. 
  04HYHG 
  058TB6
Product:   V114 23
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialTiming of Dose Administration 5.2.2
Subjects must be afebrile for at least 72 hours prior to vaccination. In this trial, V114 -1, 
V114 -2,or Prevnar 13™ will be administered as a n0.5-mL intramuscular injection at Visit 1 
(approximately  2 months of age [≥42 or ≤90 days of age]), Visit 2 (4 months of age to 1 day 
prior to 5 months of age), Visit 3 (6 months of age to 1 day prior to 7 months of age) and 
Visit 5 (12 months of age to 1 day prior to 16 months of age).  The day of the first trial
vaccination is considered Day 1 of the trial for each subject .  Sites should confirm date of 
birth with subject ’sparent/guardian and ensure that the age of the subject on the date of 
vaccination falls within the appropriate age range for each vaccination visit. Subjects should 
be observed for 30 minutes following vaccination. 
Other pediatric vaccines will be administered concomitantly on the same day as trial vaccine
according to the recommended schedule.  Concomitant oral vaccines may be administered 
prior to the trial vaccine and other injectable concomitant vaccines . Precautions must be 
taken to prevent choking during the administration of oral vaccines as aspiration of oral 
vaccines could occur if the baby  is cry ing or is agitated after receiving the injectable vaccine . 
Concomitant injectable vaccines should be administered on the same day  as trial vaccine and 
after the trialvaccine has been administered .  To avoid any confounding results, non-trial
injectable vaccines should not be administered in the same limb as trialvaccine.
Trial Blinding 5.2.3
A double -blind/masking technique will be used. V114 will be dispensed in a bl inded fashion 
by an unblinded pharmacist or qualified trial site personnel. The subject, the investigator and 
Sponsor personnel or delegate(s) who are involved in the vaccination or clinical evaluation of 
the subjects are unaware of the group assignments .
All other MRL  employ ees directly  involved with the conduct of t his trial will remain blinded 
to the subject level treatment assignment, and will receive only group level summaries of 
immunogenicit y and safety data from the analys es.
Note: Because the trialvaccine and Prevnar 13™ have a different appearance, a member of 
the trial site staff will be unblinded for the purpose of receiving, maintaining, and 
preparing/administering the trial vaccine. In order to avoid bias, the unblinded trial
person nel will have no further contact with trial subjects for any trial-related 
procedures/assessments after administration of trial vaccines, which includes all safet y 
follow up procedures . Contact between subjects and unblinded trial personnel after 
vaccination admin istration is strictly  prohibited .
See Section 7.1.4.2, Blinding/Unblinding, for a description of the method of unblinding a 
subject during the trial, should such action be warranted.
Randomization or Vaccine Allocation 5.3
Randomization will occur centrall y using aninteractive response technology (IRT), which 
may consist of interactive voice response system / integrated web response system 
(IVRS/I WRS) .There will be two V114 arms and one Prevnar 13™ arm. Subjects will be 
randomly  assigned in a 1:1:1 ratio to one of the two V114 vaccination groups or control 
(Prevnar 13™), respectively .   
  04HYHG 
  058TB6
Product:   V114 24
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialStratification 5.4
No stratification based on age, sex or other characteristics will be used in this trial.
Concomitant Medications /Vaccinations (Allowed andProhibited) 5.5
Medications or vaccinations specifically  prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for any medication or vaccination 
specificall y prohibited during the trial, discontinuation from trial therapy  or vaccination may 
be required.  The investigator should discuss any questions regarding this with the Sponsor 
Clinical Director.  The final decision on any supportive therap y or vaccination rests with the 
investigator and/or the subject's primar y physician.  However, the decision to continue the 
subject on trial therapy or vaccination schedule requires the mutual agreement of the 
investigator, the Sponsor and the subject’s legally  acceptable representative .
Any concurrent medication or medical treatment must be recorded on the appropriate 
electronic case report form (eCRF).  During the influenza season, it is anticipated that trial
subjects 6 months of age and older may be given an influenza vaccine.  Influenza vaccine 
should be administered eithe r 14 days prior to or 30 daysafter the administration of the trial
vaccine.
If a medical condition requires the use of immunoglobulin, blood, or blood products during a 
subject's participation in this trial, one of the individuals listed on the SPONSOR Contact 
Information page must be notified as soon as possibleand any such use must be documented 
on the appropriate eCRF.
The trial vaccines (V114 and Prevnar 13™) will be administered at approximately  2, 4, 6, 
and 12 to 15 months of age.  On the day of vaccination, it is important to record the use of 
any analgesic or antipy retic use on the VRC and appropriate eCRF.
Subjects should not receive systemic corticosteroids (equivalent of 2 mg/kg total daily dose 
of prednisone or 20 mg/d for persons weighing >10 kg for 14 consecutive days) starting 
from 14days prior to vaccination through 30 days after each vaccination.  Topical, 
ophthalmic and inhaled steroids are permitted.
Other pediatric vaccines will be administered concomitantly  according to the recomme nded 
schedule.  These concomitant non-trial vaccinations will be recorded on the appropriate 
eCRF.  
Concomitant vaccines (oral or injectable) should be administered on the same day as trial
vaccine. Concomitant oral vaccines may be administered prior to the trial vaccine and other 
injectable concomitant vaccines .  Precautions must be taken to prevent choking during the 
administration of oral vaccines. Other pediatric injectable vaccines administered 
concomitant lyshould be given after the trial vaccine.  To avoid any confounding results, 
non-trial injectable vaccines should not be administered in the same limb as trial vaccine.  
Documentation of which limb was used for the administration of trial vaccine should be 
recorded on the appropriate eCRF.  As the trialis reporting injection -site AEs from the trial
vaccine (and not from the concomitant vaccines), this information should also be recorded on 
the VRC to inform the parent/legal guardian of the appropriate limb to monitor for AEs 
ONLY related to the trialvaccine.  
  04HYHG 
  058TB6
Product:   V114 25
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialNo other investigational compound or device may be administered at any time during this 
trialwithout prior approval by  the SPONSOR.
Rescue Medications & Supportive Care 5.6
Infant subjects who fail to achieve adequate serologic responses following the third dose of 
trial vaccine will be offered an additional dose of licensed pneumococcal conjugate vaccine 
outside of this protocol.  Any trial subject with seroty pe-specific pneumococcal IgG (as 
measured by Pn ECL  assay) below 0.35 μg/mL for serot ype 19A (individually ) or 4 or more 
seroty pes in common between V114 and Prevnar 13™ at 1 month PD3, will be given one 
dose of licensed pneumococcal co njugate vaccine as soon as possible after serological results 
are available.  All subjects who meet the rescue criterion must be discontinued from the trial
prior to administering the additional dose of licensed pneumococcal conjugate vaccine. The 
disconti nuation date should be the date the parent/legal guardian was notified of the child’s 
meeting the rescue criterion. Adverse events or changes to medical history  occurring after the 
14 days of safety  follow up for Dose 3 and the discontinuation should be reported in the 
database; no additional immunogenicit y blood sample should be drawn. If an SAE occurs 
between the 14 days of safet y follow up for Dose 3 and the discontinuation, that event must 
be reported. The serologic threshold value of 0.35 μg/mL  was recommended by a  W HO 
expert panel as an acceptable threshold value for evaluating the clinical performance of 
pneumococcal conjugate vaccines in infants [16], [17].  Adequate treatment provisions, 
including epinephrine, should be available for immediate use should an anaph ylactic or 
anaph ylactoid reaction occur.
Diet/Activity/Other Considerations 5.7
No special dietary  restrictions apply to this trial.
Subject Withdrawal/Discontinuation Criteria 5.8
Discontinuation of Vaccination 5.8.1
Discontinuation of vaccination does no t represent withdrawal from the trial.
As certain data on clinical events beyond vaccination discontinuation may be important to 
the study , they must be collected until the end of the study , even if the subject has 
discontinued vaccination .  Therefore, subjects who discontinue trial vaccination prior to 
completion of the vaccination will still continue to participate in the trial as specified in 
Section 6.0 - Trial Flow Chart and Section 7.1.5.3 –Discontinued Subjects Continuing to be 
Monitored in the Trial. Subjects who discontinue after Visit 4 (due to lack of efficacy  or 
other reasons) are not required to continue to be monitored and will not be requested to return 
for a final monitoring visit.
Subjects may discontinue treatment at any time for any reason or be dropped from 
vaccination at the discretion of the investigator should any untoward effect occur.  In 
addition, a subject may be discontinued from vaccination by the investigator or the Sponsor 
if vaccination is inappropr iate, the trial plan is violated, or for administrative and/or other 
safet y reasons.  Specific details regarding procedures to be performed at vaccination
discontinuation are provided in Section 7.1.4 –Other Procedures. 
  04HYHG 
  058TB6
Product:   V114 26
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialA subject must be discontinued from vaccination but continue to be monitored in the trial for 
any of the following reasons:
○The subject or subject’s legally  acceptable representative requests to discontinue 
vaccination .
oThe subject’s treatment assignment has been unblinded by the investigator, Merck 
subsidiary  or through the emergency  unblinding call center. 
oThe subject has a medical condition or personal circumstance which, in the opinion of 
the investigator and/or spon sor, placed the subject at unnecessary  risk from continued 
administration of study  drug/vaccine .
For subjects who are discontinued from vaccination but continue to be monitored in the trial, 
see Section 6.0 – Trial Flow Chart, and Section 7.1.5.3 –Discontinued Subjects Continuing 
to be Monitored in the Trial for those procedures to be completed at each specified visit .
Discontinuation from vaccination is “permanent.” Once a subject is discontinued, he/she 
shall not be allowed to restart vaccination .
Withdrawal from the Trial 5.8.2
Subjects may  withdraw from the trial at any  time for any  reason.  If a subject withdraws from 
the trial, they  will no longer receive treatment or be followed at scheduled protocol visits.
A subject must be withdrawn from the tria l if:
○The subject or subject’s legally  acceptable representative withdraws consent from the 
trial.
○The subject is lost to follow -up.
oAny infant subject that fails to achieve adequate serologic responses, as described in 
Section 5.6, will be discontinue d from the trial.
Specific details regarding procedures to be performed at the time of withdrawal from the trial
including the procedures to be performed should a subject repeatedl y fail to return for 
scheduled visits and/or if the study  site is unable to contact the subject, as well as specific 
details regarding withdrawal from Future Biomedical Research are outlined in Section 7.1.4 
–Other Procedures.
Subject Replacement Strategy 5.9
A subject who discontinues from the trial will not be replaced.
Beginning and End of the Trial 5.10
The overall trial begins when written informed consent is provided for the first subject.  The 
patient participation portion of the trial ends when the last subject completes the last study-
related phone -call or visit, discontinues from the trial or is lost to follow -up (i.e. the subject is 
unable to be contacted by the investigator). For purposes of analy sis and reporting, the 
overall trial ends when the Sponsor receives the last serology assay result. 
  04HYHG 
  058TB6
Product:   V114 27
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialClinical Criteri a for Early Trial Termination 5.11
Early trial termination will be the result of the criteria specified below:
The eDMC will be provided with the following stopping rules as guidance for 
temporarily halting or terminating the trial:
All serious adverse events will be reviewed by the eDMC chairperson.  If any of the 
following events occurs, administration of trial vaccine will be temporarily  discontinued 
until a thorough review of accumulated safet y data is undertaken by the eDMC, the 
investigator, and /or the SPONSOR’s representative.   Early trial termination may result 
from this review.
Death in an y subject, unless the cause of death is due to obvious alternative etiology;
Unexpected life-threatening event in any subject, unless due to obvious alternative 
etiology . Event should not have been previously  observed with similar pneumococcal 
vaccines, or vaccines administered concomitantly in this trial;
Event which in the opinion of the investigator and/or safet y monitoring committee 
contraindicates further dosing of additional subjects.
Conclusions about the overall safet y of the investigational product will otherwise be 
determined from any SAE and solicited systemic AEs with a severe intensity  rating, 
regardless of relationship to vaccination. The relationship to trial vaccine is determined by 
the trialinvestigator. 
The trial site and SPONSOR's personnel directly  involved in the conduct of the trial will 
remain blinded a s to the treatment allocation of the trialsubject.
Subject Completion 5.12
A subject will be considered “completed” and reported as such on the appropriate eCRFs 
when he/she has received the required vaccinations and the final safet y follow -up visit (Visit 
6) has been completed. 
  04HYHG 
  058TB6
Product:   V114 28
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential6.0TRIAL FLOW CHART
Visit Number : 1, l2a, l3l4l5l6l
Visit Timing:Age:~2 months 
DOSE 1Age:~ 4 months 
DOSE 2Age:~6 m onths 
DOSE 3~1 m onth
after Visit 3Age:~12 to 15 
months DOSE 4~1 m onth after 
Visit 5
Visit Windowj:≥42 days of age 
to ≤90 days of 
age4 months of age 
to 1 day prior to 
5 months of age6 months of age 
to 1 da y prior to 
7 months of age28 to 42 days 
PD312 months of age to 1 
day prior to 16 
months of age28 to 42 days 
PD4
Administrative Procedures
Informed ConsentbX
Informed Consent for Future Biomedical Research
(FBR)c X
Inclusion/Exclusion Criteria X
Subject Identification Card X
Medical History X
Update Medical History (New condition not already 
recorded as medical history or adverse event s)X X X X X
Prior MedicationmX
Concomitant Medication Review X X X X X
Vaccination Allocation/Randomization in IRTdX
Trial Vaccine AdministrationdX X X X
Childhood VaccineseX X X X
Provide Electronic Vaccin ation Report Card (VRC) X
Review VRC datafX X X X
Clinical Procedures /Assessments
Full Physical Examination X X X X
Obtain TemperaturegX X X X
30 Minutes Postvaccination Observation PeriodkX X X X
Adverse event MonitoringfX X X X X X
Assess for Serious Adverse event sfX X X X X X
Laboratory Procedures /Assessments
Collect blood samples for immunogenicity assays (4-5 
mL)h, X XiX
Collect Buccal Swabs for Future Biomedical Research cX 
  04HYHG 
  058TB6
Product:   V114 29
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidentiala.For all vaccination visits (Visits 1 , 2, 3 and 5) , trial coordinator should review the electronic Vaccination Report Card (VRC) in the vendors database at 14 days postvaccination 
(0 to plus 5 day window) and call the parent/legal guardian if there 
is a need to address questions (document phone call in trial chart).  The site will review VRC with 
parent/legal guardian at next visit.
b.Consent must be obtained prior to any trialprocedures.
c.Informed consent for future biomedical research samples must be obtained before the collection of the buccal swab DNA samples .  Buccal swab DNA samples for analysis 
should be obtained prior to the vaccination, on Day 1, on randomized subjects only, or at a later date as soon as the informed consent is obtained.
d.In order to avoid bias, the unblinded trial personnel will have no further contact with trial subjects for any trial-related procedures/assessments following administration of the 
trial vaccines.  This includes all safety follow -up procedures. Contact between subjects and unblinded trial personnel after vaccination administration is strictly prohibited. The 
study vaccine should be removed from the refrigerator no more than 1 hour before vaccination and time of removal and time of vaccination should be noted in subject’s chart. 
e.Concomitant (or routine pediatric) vaccines are to be given according to recommended schedule. Any injectable concomitant vac cines provided at the visit must be given after 
the trial vaccine and in a separate limb, may be given during the 30-minute observation period, and do not require additional observation time . Concomitant oral vaccines may 
be administered prior to the trial vaccine and other injectable concomitant vaccine.
f.Adverse event s (serious and non-serious) are to be reported from Day 1  to 14 days following each vaccination. Serious Adverse event s are to be reported from 
treatment/randomization through 30 days following the last study vaccina tion.
g.Pre-vaccination temperatures taken by trial staff at Visits 1, 2, 3 and 5. Subjects who have febrile illness (rectal temperature ≥38.1°C [≥100.5°F] or axillary temperature 
≥37.8°C [≥100.0°F]) occurring at or within 72 hours of Visits 1, 2, 3 and 5 must be rescheduled. Parent/legal guardian to measure and record temperature per VRC instructions.
h.Leftover serum samples collected from the main trialwill be stored for future use if the FBR consent is signed.
i.Collect blood prior to vaccination.
j.Day of first trialvaccination = Day 1 of trial.  To calculate visit windows for subsequent trial vaccinations , confirm subject DOB and ensure the age of the subject will fall 
within the appropriate age range for each trialvisit.
k.Start and stop time for the 30 minute post vaccination observation period must be noted in subject chart.
l.Subjects who discontinue the study early may be asked to return for a post -trial visit,  see Section 7.1.5.3 for details.
m.Record prior medications taken by the subject within 30 days befor e first vaccination.    
  04HYHG 
  058TB6
Product:   V114 30
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential7.0TRIAL PROCEDURES
Trial Procedures 7.1
The Trial Flow Chart -Section 6.0summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary  to 
perform these procedures at unscheduled time points if deemed clinically necessary  by the 
investigator.
Furthermore, additional evaluations/testing may  be deemed necessary  by the investigator and 
or the Sponsor for reasons related to subject safety . In some cases, such evaluation/testing 
may be potentially  sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent be obtained from the subject ’s legally 
acceptable representative .  In these cases, such evaluations/testing will be performed in 
accordance with those regulations.
Administrative Procedure s 7.1.1
Informed Consent 7.1.1.1
The investigator or qualified designee must obtain documented consent from each potential 
subject’s legally  acceptable representative prior to participating in a clinical trial or Future 
Biomedical Research .If there are changes to the subject’s status during the trial (e.g.,health 
or age of majority  requirements ), the investigator or qualified designee must ensure the 
appropriate consent is in place. 
7.1.1.1.1 General Informed Consent
Consent must be documented by the subject’s legally  acceptable representative’s dated 
signature on a consent form along with the dated signature of the person conducting the 
consent discussion. 
A copy  of the signed and dated consent form should be given to the subject’s legally 
accept able representative before that subject’s participation in the trial.
The initial informed consent form, any subsequent revised written informed consent form 
and any written information provided to the subject’s legall y acceptable representative must 
recei ve the IRB/ERC’s approval/favorable opinion in advance of use.  The subject’s legall y 
acceptable representative should be informed in a timely  manner if new information becomes 
available that may be relevant to willingness for the subject to continue parti cipation in the 
trial.  The communication of this information will be provided and documented via a revised 
consent form or addendum to the original consent form that captures the subject’s legall y 
acceptable representative’s dated signature.
Specifics about a trial and the trial population will be added to the consent form template at 
the protocol level.  
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations 
and Sponsor requirements. 
  04HYHG 
  058TB6
Product:   V114 31
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential7.1.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or qualified designee will explain the Future Biomedical Research consent 
to the subject ’s legally acceptable representative , answer all of his/her questions, and obtain 
written informed consent before performing any procedure related to the Future Biomedical 
Research sub-trial.  A  c opy of the informed consent will be given to the subject ’s legall y 
acceptable representative .
Inclusion/Exclusion Criteria 7.1.1.2
All inclusion and exclusion criteria will be review ed by the investigator or qualified designee 
to ensure that the subject qualifies for the trial.
Subject Identification Card 7.1.1.3
The legally  acceptable representative for each subject will be given a Subject Identification 
Card identify ing the subject as a par ticipant in a research trial. The card will contain trial site 
contact information (including direct telephone numbers) to be utilized in the event of an 
emergency . The investigator or qualified designee will provide the legally  acceptable 
representative for each subject with the Subject Identification Card immediately  after written 
informed consent is provided. At the time of treatment allocation/randomization, site 
personnel will add the treatment/randomization number t o the Subject Identification C ard.
The subject identification card also contains contact information for the emergency  
unblinding call center so that a health care provider can obtain information about trial 
medication/vaccination in emergency  situations where th e investigator is not avail able.
Medical History 7.1.1.4
A medical history  will be obtained at baseline by the investigator or qualified designee.   At 
all subsequent trial visits (Visit 2, 3, 4, 5, and 6) the investigator or qualified designee will 
record any condition not alread y recorded as baseline medical history  or adverse events on 
the update medical history eCRF.
Prior and Concomitant Medications Review 7.1.1.5
7.1.1.5.1 Prior Medications
The investigator or qualified designee will review prior medication use, including any 
protocol -specified washout requirement, and record prior medication taken by the subject 
within 30 day sbefore first vaccination .
7.1.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by the subject 
during the trial.
Any concurrent medic ation or medical treatment must be recorded on the appropriate 
electronic case report form (eCRF).  On the day of vaccination, it is important to record the 
use of an y analgesic or antipy retic use on the VRC and appropriate eCRF. 
  04HYHG 
  058TB6
Product:   V114 32
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialIf a medical condition required the use of immunoglobulins, blood, or blood products during 
a subject’s participation in this study , one of the individuals listed on the SPONSOR Contact 
Information page must be notified as soon as possible and any such use must be documented 
on the appropriate eCRF.
Assignment of Screening Number 7.1.1.6
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization or treatment allocation.  Each 
subject will be a ssigned only one screening number.  Screening numbers must not be re -used 
for different subjects.
Any subject who is screened multiple times will retain the original screening number 
assigned at the initial screening visit.
Specific details on the screenin g visit requirements are provided in Section 7.1.5.1.  
Assignment of Treatment/ Randomization Number 7.1.1.7
All eligible subjects will be randoml y allocated and will receive a treatment/ randomization 
number.  The treatment/ randomization number identifies the subject for all procedures 
occurring after treatment allocation/ randomization.  Once a treatment/ randomization number 
is assigned to a subject, it can never be re -assigned to another subject.
A single subject cannot be assigned more than 1 treatment/ randomization number.
Trial Compliance 7.1.1.8
7.1.1.8.1 Study Vaccination
All subjects will be given a card, at the time of screening, identify ing them as participants in 
a research study . The card will contain contact information (including direct telephone 
numbers) to be utilized in the event of an emergency .
Unblinded study  personnel not otherwise involved in the conduct of the study  will prepare 
and administer the study vaccine. Unblinded study  personnel should not have contact with 
subjects for any study -related procedures/assessments after administration of study  vaccines, 
which includes all safet y follow up procedures. Of note, all vaccine must be stored at 2°C to 
8°C (35.6°F to 46.4°F).  The syringes must remain refrigerated (2 to 8ºC) until the time of 
administration; study  vaccine must be administered within one (1) hour of removal from the 
refrigerator or discarded and replaced via the IRTsystem.
Prior to administration of study  vaccine (V114 Lot 1, V114 Lot 2, or Prevnar 13™ ), shake 
vigorousl y to obtain a homogenous white suspension. If appearance is otherwise, do not 
administer. Do not use the vaccine if it cannot be resuspended.  Visual inspection of study 
vaccine for particulate matter and discoloration prior to administration should be completed.  
The study  vaccine should not be used if particulate matter or discoloration is found.  Partial 
or empty vaccine syringes should be properl y discarded as biohazardous waste. Investigator 
sites should follow instructions for the Clinical Supplies Return Form and contact your 
SPONSOR representative for review of shipment and form before shipping. 
  04HYHG 
  058TB6
Product:   V114 33
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialAll safet y and immunogenicity  assessments will be conducted by blinded personnel, and the 
subject or subjects’ parents/guardians will be blinded to the study  vaccine received by the 
study  subject.  Vaccination information, such as Component Identification Number and time 
of vaccination, must be recorded on the appropriate eCRF as per the Data Entry  Guideline 
(DEG) instructions.
Subjects wil l be randomly assigned to 1 of 3 vaccination arms: 
(1) V114 Lot 1
(2) V114 Lot 2
(3) Prevnar 13™  
A 0.5-mL intramuscular dose of study  vaccine will be administered to healthy  infants at 
approximately  2, 4, 6, and 12 to 15 months of age. 
The vaccines should be administered at a 90° angle in the anterolateral thigh muscle using 
the provided syringes with the following needle length a
nd gauge specifications1: 1 inch 
needle, 22 to 25 gauge for infants (2-6 months) and 1 to 1¼ inch needle, 22 to 25 gauge for 
toddlers (12 to 15 months). (See CDC Pink Book, Appendix D for additional details ).
To ensure that parents do not become confused regarding the location of the study  vaccine 
injection -site, Doses 1, 2, and 3 of the study  vaccine are to be administered in the same limb 
(e.g.,if the study  vaccine is provided in the right thigh for dose 1, subsequent doses should 
also be provided in th
e right thigh). Dose 4 may  be administered in the deltoid region instead 
of the thigh, at the discretion of the investigator2.If an abnormality  (i.e., rash) is observed at 
the site where the previous dose of the study  vaccine was administered, it is permissible to 
use the anterolateral muscle of the other limb to administer the following dose of the study 
vaccine.  (See attachment, CDC Pink Book, Appendix D for additional details). 
7.1.1.8.2 Concomitant Vaccinations
No other investigational compound or device may be administered at any time during this 
study  without prior approval by  the SPONSOR.
                                                
1Needles provided in Prevnar 13™ blister packages may also be used.
2Per investigator discretion, dose 4 can be adm inistered in the deltoid muscle instead of the anterolateral thigh 
muscle; if given in the deltoid muscle, the needle length should be 5/8 to 1 inch (a 5/8 inch needle may be 
used only if the skin is stretched tight, subcutaneous tissue is not bunched, and injection is made at a 90-
degree angle). 
  04HYHG 
  058TB6
Product:   V114 34
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialThe study  vaccines will be administered at approximately  2, 4, 6, and 12 to 15 months of age.  
Other pediatric vaccines will be administered concomitantly  according to the mandated 
schedule in the site’s country /region. These concomitant non-study  vaccinations will be 
recorded on the appropriate eCRF. Combination MMRV vaccines should not be given in 
this study ; however, MMR and Varicella vaccines are permitted if administered 
concomitantly  in 2 separate limbs.
Concomitant vaccines (oral or injectable) should be administered on the same day as study  
vaccine. Concomitant oral vaccines may  be administered prior to the study  vaccine and other 
injectable concomitant vaccines .  Precautions must be taken to prevent choking during the 
administration of oral vaccines.   Concomitant injectable vaccines should be administered 
after the study  vaccine.  To avoid any confounding results, non-study  injectable vaccines 
should not be administered in the same limb as study  vaccine.  Documentation of which limb 
was used for the administration of study  vaccine should be recorded on the appropriate 
eCRF.  As we are requesting the reporting of injection -site adverse experiences from the 
study  vaccine (and not from the concomitant vaccines), this information should also be 
recorded on the VRC to inform the parent/legal guardian of the appropriate limb to monitor 
for adverse experiences ONLY related to the study vaccine.  
During the influenza season, it is anticipated that trial subjects 6 months of age and older 
may be given an influenza vaccine.  Influenza vaccine should be adm inistered either 14 days
prior to or 30 day safter the administration of the trialvaccine.
Dispense Electronic Vaccination Report Cards 7.1.1.9
The vaccination report card was developed to be administered electronically  via a hand -held 
device.  This item was structured as recommended in the final FDA Patient Reported 
Outcome (PRO) Guidance.  The investigator or delegate will train the subject ’sparent/legal 
guardian in the use of the electronic vaccination report card prior to dispensing it at Visit 1.  
Body tempe ratures, injection -site AEs, VRC -prompted systemic complaints, other 
complaints or illnesses, and medications will be recorded on the VRC throughout the study .  
The investigator or delegate will review the data captured on the VRC with the parent/legal 
guardian at Visit 2 through Visit 6.
Interruptions from the protocol specified vaccination require consultation between the 
investigator and the Sponsor and written documentation of the collaborative decision on 
subject management.
Clinical Procedures/Assessments 7.1.2
Physical Examinations 7.1.2.1
Afull physical examination will be performed at Visits 1, 2, 3, and 5.. Any clinically  
significant abnormality  will be recorded on the appropriate eCRF. 
The full phy sical examination procedures include obtaining vital signs (heart rate, respiratory 
rate, and body  temperature), auscultation of the heart and lung, and examination of the 
abdomen, an assessment of the head, eyes, ears, nose and throat (HEENT), skin, lymph 
nodes, neurological s ystem, and musculoskeletal system. 
  04HYHG 
  058TB6
Product:   V114 35
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialFindings related to the physical examinations should be documented in the subject 
chart/source documentation. 
Temperature 7.1.2.2
Pre-vaccination rectal temperatures will be taken by trial staff at Visits 1, 2, 3, and 5.  
Subjects who have febrile illness (rectal temperature ≥38.1°C [≥100.5°F] or axillary 
temperature ≥37.8°C [≥100.0°F]) occurring at or within 72 hours of Visits 1, 2, 3 and 5 must 
be rescheduled. Rectal is the preferred method ofobtaining subject’s temperature.  Axillary  
(underarm) is an acceptable method but temperature needs to be confirmed by rectal 
measurement .If an axillary  temperature is performed and is reported to be ≥37.8°C 
(≥100.0°F), it must be confirmed with a rectal temperature.  In this case, both axillary  and 
rectal temperatures must be recorded on the VRC.  Temperature readings should be taken at 
approximately  the same time each day .  Use of temporal or tympanic thermometers to collect 
temperature for this study i s prohibited.
The subject’s parent/legal guardian will be asked to record a rectal temperature reading on 
the VRC from Day 1 through Day 7 following each vaccination.  Temperature measurement 
must be recorded in the VRC if fever is suspected during Day  8 through Day  14.  
Assess Adverse Experiences 7.1.2.3
Study  subjects will be observed for 30 minutes postvaccination for any immediate AEs.  The 
time at which the event occurred within the 30 minute timeframe, as well as the event itself 
and resolution of the event must be recorded on the appropriate eCRF.  Instructions on 
completing the VRC will be reviewed with each study  subject's parent/legal guardian.  
Injection -site and systemic AEs occurring Day 1 through Day 14 following each vaccination 
will be recorded by the subject's parent/legal guardian on the electronic VRC; this includes 
VRC -prompted injection -site AEs (redness, swelling, hard lump, and pain/tenderness) and 
VRC -prompted systemic AEs (irritability , drowsiness, appetite lost, hives or welts).  See
Sectio n 7.2 for detailed information concerning the assessment and recording of AEs.
Laboratory Procedures/Assessments 7.1.3
Details regarding specific laboratory  procedures/assessments to be performed in this trial are 
provided below. The total amount of blood/tissue to be drawn/collected over the course of 
the trial (from pre-trial to post-trial visits), including approximate blood/tissue volumes 
drawn/collected b y visit and by sample type per subject can be found in Section 12.4.
Laboratory Safety Evaluations (Hemat ology, Chemistry and Urinalysis) 7.1.3.1
There are no laboratory  safet y evaluations required by the protocol. 
  04HYHG 
  058TB6
Product:   V114 36
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialBlood Collection for Immunogenicity Assays 7.1.3.2
Subjects will have blood drawn (approximately  4-5 mL) at 3 time points: (1) approximately  1 
month following the third study  vaccination (PD3), (2) immediately  prior to administration 
of the fourth study  vaccination, and (3) approximately  1 m onth following the fourth study 
vaccination (PD4).  Sera will be used to measure vaccine -induced pneumococcal -specific 
immune responses (IgG and opsonophagocy tic killing activity  [OPA]).  These serum samples 
will be assay ed using the Meso -Scale Discovery  MSD Pn ECL assay, which was developed 
by Merck & Co., Inc. for the measurement of pneumococcal capsular polysacch aride IgG 
antibodies. Serum samples will also be assay ed using a 4-Fold Multiplex Opsonophagocy tic 
Assay  which Merck has developed and implemented in collaboration with  
. If a serum sample does not have eno ugh volume for 
both the IgG and OPA testing, the IgG testing will take priority .  OPA will be evaluated in 
approximately  50% of subjects enrolled at US investigator sites with sufficient PD3 sera 
available to perform both the PnECL  and the OPA testing on all 15 seroty pes in V114.  
OPAs will be conducted at pre-dose 4 and at PD4 for all of the subjects who had PD3 OPAs 
performed and for which there is sufficient serum.  Any remaining sera will be retained for 
future biomedical research (e.g., pneumococcal assay development) providing the future 
biomedical research (FBR) consent has been signed.
Pneumococcal Electrochemiluminescence (Pn ECL) Assay
The purpose of the Pn ECL  assay is to detect serum IgG antibod y to the pneumococcal 
polysaccharides (PnPs) seroty pes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 
and 33F before and after vaccination with PnPs containing vaccine(s).  The serot ypes are 
assay ed in a group of 7 (types 1, 5, 6A, 7F, 19A, 22F, 33F) and a group of 8 (types 3, 4, 6B, 
9V, 14, 18C, 19F, 23F). Antibodies to these seroty pes are measured in mass units (μg/mL) 
read from a standard curve prepared from a pool of adult serum, collected postvaccination 
with a PPV23 and referred to as 007sp.
The assay  is based on the MSD™ technology  which employs multi -spot microtiter plates 
fitted with a series of electrodes associated with the bottom of the well.  Seroty pe-specific 
PnPs are spotted to the MSD™ plates and used as the solid phase antigen.  Experimental, 
control, and standard curve sera are pre-adsorbed with pneumococcal cell wall 
polysaccharide (CPs) and non-vaccine heterologous seroty pe PnPs (types 25 and 72) to 
reduce the nonspecific antibody  response in the assay , and subsequently incubated in the 
PnPs antigen -coated wells.  Anti-PnPs, which bind to the solid phase PnPs, are subsequentl y 
detected with a ruthenium -labeled anti-human IgG conjugate.  Plates are read by measure of 
the chemiluminescent signal emitted from the ruthenium tag upon electrochemical 
stimulation initiated at the electrod e surfaces of the microplates.  The intensity  of the 
luminescence is directly  proportional to the amount of anti -PnPs in the sample. 
  04HYHG
PPD
PPD 
  058TB6
Product:   V114 37
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialStandard curves are prepared from the human Pneumococcal Standard Reference Serum, 
007sp (Center for Biologics Evaluation and Research, U.S. FDA).  The following standard 
and controls are run in each assay : (a) a 12-point standard curve which includes a serum 
diluent blank and an 11-point, 2.5-fold dilution series of 007sp that begins with an initial 
dilution of 1:400; (b) two different dilutions (1:1000 and 1:10,000) of Giebink serum 16 
(G16) and one dilution (1:1000) of Giebink serum 5 (G5), both individu al human immune 
sera obtained after vaccination with PPV23 by ; 
(c) a serum sample from a previous Merck clinical trial tested at 1:10,000 dilution.  
Clinical testing on the Pn ECL  assay will be performed at Merck Research Laboratories 
(MRL ) or its designated partners that are qualified to perform the assay .
Multiplex Opsonophagocytic Assay (MOPA -4)
The 4-Fold Multiplexed Opsonophagocy tic Killing Assay  for antibodies against 
Streptococcus pneumoniae (MOPA -4) is used to measure sera of patients vaccinated with 
multivalent pneumococcal vaccines for antibody titers (opsonic activity /killing) against the 
capsular polysaccharides for specific S. pneumoniae serot ypes.  The method is multiplexed 
permitting testing of 4 serotypes per run, eliminating excessive use of infant sera.  The assay  
utilizes complement (baby  rabbit source), a critical component, which requires qualification 
prior to use in the MOPA -4.  The opsonophagocy tic killing assay  (OPA) also utilizes HL-60 
human Promy elocy tic Leukemia cells which are transformed into phagocy tes for this assay .  
Complement is added in addition to bacterial strains (pneumococcal serot ypes 1, 3, 4, 5, 6A, 
6B, 7F, 9V, 14, 19A, 18C, 19F, 22F, 23F, and 33F; strains tested in groups of4) and patient 
sera.  The ability  of antibodies in patient sera, at a series of dilutions, to initiate the killing of 
the pneumococcal bacteria is the basis for assignment of antibod y titer of the sample.  The 
opsonization titers (OT) are defined as the serum dilution that kills 50% of bacteria and are 
determined using a linear interpolation algorithm.  The results are reported as the reciprocal 
of the dilution.  The MOPA -4 was developed and published by  
 .
Merck has been involved in the development and implementation of the MOPA -4 in 
collaboration with  and 
with   Both 
labs are qualified to generate clinical results and one of them will support MOPA -4 testing 
for this study .
Clinical testing on the MOPA assay  will be performed at Merck Research Laboratories 
(MRL ) or its designated partners that are qualified to perform the assay .
Future Biomedical Research Sample s 7.1.3.3
The following specimens are to be obtained as part of Future Biomedical Research:
DNA for future research
Leftover serum samples collected in the main study . 
  04HYHG
PPD
PPD
PPD
PPD 
  058TB6
Product:   V114 38
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialOther Procedures 7.1.4
Withdrawal/Discontinuation 7.1.4.1
Subjects who discontinue/withdraw from vaccination prior to completion of the vaccination 
regimen should be encouraged to continue to be followed for all remaining study  visit s.
When a subject discontinues/withdraws from participation in the trial , all applicable activities 
scheduled for the final trial visit should be performed at the time of discontinuation.  Any 
adverse events which are present at the time of discontinuation /withdrawal should be 
followed in accordance with the safety  requirements outlined in Section 7.2 -Assessing and 
Recording Adverse Events .  Any  infant subject fails to achieve adequate serologic responses, 
as described in Rescue Medications & Supportive Care Section 5.6, will be discontinued 
from the trial prior to administering the additional dose of licensed pneumococcal conjugate 
vaccine .
7.1.4.1.1 Withdrawal From Future Biomedical Research
A subject ’sconsent for Future Biomedical Research may be withdrawn by the subject’s 
legally  acceptable representative .  A subject ’s consent may be withdraw nat any time by 
contacting the principal investigator for the main trial.  If medical records for the main trial 
are still available, the investigato r will contact the Sponsor using the designated mailbox 
(clinical.specimen.management@merck.com).  Subsequently , the subject's consent for Future 
Biomedical Research will be withdrawn.  A  l etter will be sent from the Sponsor to the 
investigator confirming the withdrawal. It is the responsibility  of the investigator to inform 
the subject of completion of withdrawal.  Any analyses in progress at the time of request for 
withdrawal or alread y performed prior to the request being received by the Sponsor will 
continue to be used as part of the overall research trial data and results.  No new analyses 
would be generated after the request is received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by regulatory  authorities to retain the main trial records) or 
the specimens have been completely  anony mized, there will no longer be a link between the 
subject’s personal information and their specimens.  In this situation, the request for 
specimen withdrawal cannot be processed .
7.1.4.1.2 Failure To Return For Scheduled Visits and/or Unable to Contact The 
Subject
If a subject fails to return to the clinic for a required study  visit and/or if the site is unable to 
contact the subject, the following pro cedures are to be performed:
The site must attempt to contact the subject and reschedule the missed visit. If the 
subject is contacted, the subject should be counseled on the importance of 
maintaining the protocol -specified visit schedule. 
  04HYHG 
  058TB6
Product:   V114 39
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialThe investigator or designee must make every  effort to regain contact with the subject 
at each missed visit (e.g. phone calls and/or a certified letter to the subject’s last 
known mailing address or locally  equivalent methods). These contact attempts shoul d 
be documented in the subject’s medical record.
Note: A subject is not considered lost to follow up until the last scheduled visit for 
the individual subject. The amount of missing data for the subject will be managed 
via the pre- specified data handling and anal ysis guidelines.
Subject Blinding/Unblinding 7.1.4.2
When the investigator or delegate needs to identify  the vaccine used by a subject and the 
dosage administered in case of emergency  e.g., the occurrence of serious adverse 
experiences, he/she will contact the emergency  unblinding call center by  telephone and make 
a request for emergency  unblinding.  As requested by the investigator or delegate the 
emergency  unblin ding call center will provide the information to him/her promptly  and 
report unblinding to the sponsor.  Prior to contacting the emergency  unblinding call center to 
request unblinding of a subject’s treatment assignment, the investigator or delegate must 
enter the intensity  of the adverse experiences observed, the relation to study  vaccine, the 
reason thereof, etc., in the medical chart etc.Subjects whose treatment assignment has been 
unblinded by the investigator/delegate and/or non-study  treating physician must be 
discontinued from study  vaccine , but should continue to be monitored in the trial.
Additionally , the investigator must go into the IVRS system and perform the unblind in the 
IVRS system to update vaccine disposition.  In the event that the emerg ency  unblinding call 
center is not available for a given site in this trial, IVRS/I WRS should be used for emergency 
unblinding in the event that this is required for subject safet y.
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., 
date, reason and person performing the unblinding ) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible. Only  the principal investigator or 
delegate and the respective subject’s code should be unblinde d. Other t rial site personnel and 
Sponsor personnel directly  associated with the conduct of the trial should not be unblinded.
Subjects whose treatment assignment has been unblinded by the investigator/delegate and/or 
non-study  treating physician must be discontinued from study  vaccine , but should continue 
to be monitored in the trial .
Domiciling 7.1.4.3
Infant subjects will report to the Clinical Research Unit (CRU) on the day of the 
administration of study  vaccine (Visit 1, 2, 3, and 5) and remain in the unit for 30 minutes 
postvaccination.  At the discretion of the investigator, subjects may  be requested toremain in 
the CRU longer .Infants will return to the CRU at Visits 4 and 6 for blood draws. 
  04HYHG 
  058TB6
Product:   V114 40
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialCalibration of Critical Equipment 7.1.4.4
The investigator or qualified designee has the responsibility  to ensure that any critical device
or instrument used for a clinical evaluation/test during a clinical trial that provides important 
information about inclusion/exclusion criteria and/or safet y or efficacy  parameters shall be 
suitably  calibrated and maintained to ensure that the data obtained is reliable and/or 
reproducible.  Documentation of equipment calibration must be retained as source 
documentation at the trial site.
Critical Equipment for this trial includes:
Refrigerators
-20° freezers
Centrifuges
Visit Requirements 7.1.5
Visit requirements are outlined in Section 6 .0-Trial Flow Chart.   Specific procedure -related 
details ar e provided above in Section 7.1 -Trial Procedures.
Screening 7.1.5.1
Screening procedures will be performed at Visit 1.  A separate screening visit is not required.
Vaccination Visits 7.1.5.2
Subjects will be required to come to the clinic for 6 visits.  See Section 6.0 for details.
Discontinued Subjects Continuing to be Monitored in the Trial 7.1.5.3
Subjects who discontinue from the trial after visits 1, 2, 3 or 5 (vaccination visits) but agree 
to continue to be monitored in the trial will be requested to return for a final mon itoring visit .
Subjects who discontinue after Visit 4 (due to lack of efficacy  or other reasons) are not 
required to continue to be monitored and will not be requested to return for a final monitoring 
visit.
Subjects returning for a final monitoring visit will be required to return to clinic 
approximately  14 days after the last vaccination for the post-trial visit. The following will be 
completed at this visit : review of VRC data, and adverse event monitoring. If the post-trial 
visit occurs less than 14 days after the last vaccination , a subsequent follow -up phone call 
should be made at 14 days post the last dose of trial drug to determine if any adverse events 
have occurred since the post -trial clinic visit. 
  04HYHG 
  058TB6
Product:   V114 41
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialAssessing and Recording Adverse Events 7.2
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily 
have to have a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding, for example), 
symptom, or disease temporally  associated with the use of a medicinal product or protocol -
specified procedure, whether or not considered related to the medicinal product or protocol -
specified procedure.  Any worsening (i.e., any clinically  significant adverse change in 
frequency  and/or intensity ) of a preexisting condition that is temporally  associated with the 
use of the Sponsor’s product, is also an adv erse event.
Changes resulting from normal growth and development that do not vary significantl y in 
frequency  or severit y from expected levels are not to be considered adverse events.  
Examples of this may include, but are not limited to, teething, typical crying in infants and 
children and onset of menses or menopause occurring at a ph ysiologically  appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol -specified procedure, whether investigational (including placebo 
or active comparator medication) or marketed, manufactured by, licensed by, provided by or 
distributed by  the Sponsor for human use.
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accidental or intentional), from abuse and from withdrawal.
All adverse events that occur after the consent form is signed but before 
allocation/ randomization must be reported by the investigator if they cause the subject to be 
exclude d from the trial, or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure. From the time of allocation/randomization through 14 days (42 days for live 
attenuated vaccines) following the first vaccination(s) and from the time of any subsequent 
vaccination(s) through 14 days (42 days for live attenuated vaccines) thereafter, all adverse 
events must be reported by the investigator. Such events will be recorded at each 
examination on the Adverse Event case report forms/worksheets. The reporting timeframe 
for adverse events meeting any serious criteria is described in section 7.2.3.1. The 
investigator will make every  attempt to follow all subjects with non-serious adverse events 
for outcome.
Electronic reporting procedures can be found in the Electronic Data Capture (EDC )data 
entry  guidelines. Paper reporting procedures can be found in the Investigator Trial File 
Binder (or equivalent).
Definition of an Overdose for This Protocol and Reporting of Overdose to the 7.2.1
Sponsor
In this trial, an overdose isthe administration of more than 1 dose of any individual study 
vaccine in an y 24-hour period . 
  04HYHG 
  058TB6
Product:   V114 42
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialIf an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product or 
vaccine, the adverse event(s) is reported as a non-serious adverse event, unless other serious 
criteria are met .
If a dose of Sponsor's product or vaccine meeti ng the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory  results, the overdose is 
reported as a non-serious adverse event using the terminology  “accidental or intentional 
overdose without adverse effec t.”
All reports of overdose with and without an adverse event must be reported by the 
investigator within 24 hours to the Sponsor either by electronic media or paper. Electronic 
reporting procedures can be found in the EDC data entry  guidelines. Paper repo rting 
procedures can be found in the I nvestigator Trial File Binder (or equivalent) .
Immediate Reporting of Adverse Events to the Sponsor 7.2.2
Serious Adverse Events 7.2.2.1
A serious adverse event is any adverse event occurring at any dose or during any use of 
Sponsor's product that:
●Results in death;
●Is life threatening;
●Results in persistent or significant disability /incapacity ;
●Results in or prolongs an existing inpatient hospitalization;
●Is a congenital anomal y/birth defect;
●Is an other important medical event .
Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same timeframe 
as SAEs to m eet certain local requirements.
●Is a c ancer;
●Is associated with an overdose.
Refer to Table 2for additional details regarding each of the above criteria.  
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any serious adverse event, or follow up to a serious adverse event, 
including death due to any  cause, that occurs to any  subject must be reported within 24 hours 
to the Sponsor if it causes the subject to be excluded from the trial, or is the result of a 
protocol -specified intervention, including but not limited to washout or discontinuation of 
usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 30days 
following the last study vaccination, any serious adverse event, or follow up to a serious 
adverse event, including death due to any cause, whether or not related to the Sponsor's 
product, must be reported within 24 hours to the Sponsor either by  electronic media or paper. 
Electr onic reporting procedures can be found in the EDC data entry  guidelines. Paper 
reporting procedures can be found in the Investigator Trial File Binder (or equivalent). 
  04HYHG 
  058TB6
Product:   V114 43
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialAdditionally , any serious adverse event brought to the attention of an investigator who is a 
qualified physician at any time outside of the time period specified in the previous paragraph 
also must be reported immediately  to the Sponsor if the event is either:
1. A death that occurs prior to the subject completing the trial, but outside the time period 
specified in the previous paragraph.
or
2. A serious adverse event that is considered by  an investigator who is a qualified phy sician 
to be vaccine related.
All subjects with serious adverse events must be followed up for outcome.
Events of Cl inical Interest 7.2.2.2
There are no Events of Clinical Interest being collected in this trial.
Evaluating Adverse Events 7.2.3
An investigator who is a qualified physician will evaluate all adverse events with respect to 
the elements outlined in Table 2. The investigator’s assessment of causality  is required for 
each adverse event.  Refer to Table 2for instructions in evaluating adverse events. 
  04HYHG 
  058TB6
Product:   V114 44
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialTable 2  Evaluating Adverse Events
Maximum Mild awareness of sign or symptom, but easily tolerated (for pediatric trials, awareness of symptom, but easily tolerated)
Intensity Moderate discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)
Severe incapacitating with inability to work or do usual activity (for pediatric trials, extremely distressed or unable to do usual activities) 
Injection site redness or swelling or hard lump from the day o f vaccination through Day 14post-vaccination will be evaluated by 
maximum size.
Seriousness A serious adverse event (AE) is any adverse event occurring at any dose that:
†Results in death; or
†Is life threatening; orplaces the subject, in the view of the investigator, at immediate risk of death from the event as it occurred [Note: This does not include an 
adverse event that, had it occurred in a more severe form, might have caused death.]; or
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay, even if the 
hospitalization is a precauti onary measure for continued observation.   (Note: Hospitalization for an elective procedure to treat a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre -existing condition is a clinical condition that is diagnosed prior tothe use of a Merck product and is documented in the 
patient’s medical history. ); or
†Is a congenital anomaly/birth defect   (in offspring of subject taking the product regardless of time to diagnosis); or
Is a cancer (although not serious per ICH defin ition, is reportable to the Sponsor within 24 hours to meet certain local requirements; or
Overdose, although not serious per ICH definition, whether accidental or intentional, with or without an accompanying adverse event/serious adverse event, is
reportable to the Sponsor within 24 hours to meet certain local requirements.
Other important medical events that may not result in death, not be life threatening, or not require hospitalization may be considered a serious adverse event when, 
based upon appropriate medical judgment, the event may jeopardize the subject and may require medical or surgical intervention to preven t one of the outcomes listed 
previously (designated above by a †).
Duration Record the start and stop dates of the adverse event. If less than 1 day, indicate the appropriate length of time and units
Action taken Did the adverse event cause the test vaccine to be discontinued?
Relationship 
to test vaccine Did the test vaccine cause the adverse event?   The determination of the l ikelihood that the test vaccine caused the adverse event will be provided by an investigator who 
is a qualified physician.  The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensur es that a 
medically qualified assessment of causality was done.  This initialed document must be retained for the required regulatory t ime frame.  The criteria below are intended 
as reference guidelines to assist the investigator in assessing the likelihoo d of a relationship between the test vaccine and the adverse event based upon the available 
information.  
The following components are to be used to assess the relationship between the test vaccine and the AE; the greater the correlation with the componen ts and their 
respective elements (in number and/or intensity), the more likely the test vaccine caused the adverse event:
Exposure Is there evidence that the subject was actually exposed to the test vaccine such as:  reliable history, acceptable compliance assessment 
(e.g., diary), seroconversion or identification of vaccine virus in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the test vaccine? 
Is the time of onset of the AE compatible with a vaccine -induced effect?
Likely Cause Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or
environmental factors 
  04HYHG 
  058TB6
Product:   V114 45
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialRelationship The following components are to be used to assess the relationship between the test vaccine and the AE:  (continued)
to test vaccine Dechallenge (not applicable for vaccines)
(continued) Rechallenge Was the subject reexposed to the test vaccine in this trial?
      If yes, did the AE recur or worsen?
          If yes, this is a positive rechallenge.    If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose 
vaccine trial.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE 
BEEN CAUSED BY THE TEST VACCINE, OR IF REEXPOSURE TO THE TEST VACCINE POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR
CLINICAL DIRECTOR AND THE INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE.
Consistency with Trial 
Vaccine ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the test vaccine or vaccine class 
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified physician according to his/her best clinical judgment, including 
consideration of the above elements.  
Record one of the following: Use the following criteria as guidance (not all criteria must be present to be indicative of a vaccine relationship) .
Yes, there is a reasonable possibility of 
vaccine relationship.There is evidence of exposure to the test vaccine.  The temporal sequenc e of the AE onset relative to the administration of the test vaccine 
is reasonable.  The AE is more likely explained by the test vaccine than by another cause.
No, there is not a reasonable possibility of 
vaccine relationshipSubject did not receive the test vaccine OR temporal sequence of the AE onset relative to administration of the test vaccine is not 
reasonable OR the AE is more likely explained by another cause than the Sponsor’s product .  (Also entered for a subject with overdose 
without an associated AE.) 
  04HYHG 
  058TB6
Product:   V114 46
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialSponsor Responsibility for Reporting Adverse Events 7.2.4
AllAdverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations , i.e., per ICH Topic E6 (R1) 
Guidelines for Good Clinical Practice .
TRIAL GOVERNANCE AND OVERSIGHT 7.3
Executive Oversight Committee 7.3.1
The Executive Oversight Committee (EOC) comprises members of Sponsor Senior 
Management.  The EOC will receive and decide upon any recommendations made by the 
eDMCregarding the trial.
Data Monitoring Committee 7.3.2
To supplement the routine trial monitoring outlined in this protocol, an external Data 
Monitoring Committee (DMC) will monitor the interim data from this trial.  The voting 
members of the committee are external to the Sponsor.  The members of the DMC must not 
be involved with the trial in any other way (e.g., they cannot be trial investigators) and must 
have no competing interests that could affect their roles with respect to the trial. 
The DMC will make recommendations to the EOC regarding steps to ensure both subject 
safety and the continued ethical integrity  of the trial.  Also, the DMC will review interim trial 
results, consider the overall risk and benefit to trial participants (see Section 8.7-Interim 
Analy ses) and recommend to the EOC if the trial should continue in accordance with the 
protocol.
Specific details regarding composition, responsibilities ,and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team; meeting 
facilitation; the trial governance structure; and requirements for and proper documentation of 
DMC reports, minutes, and recommendations will be described in a separate charter that is 
reviewed and approved by the DMC.  The DMC will monitor this trial at approximately  4 
separate time points, two of which will only contain trial safet y data.  The DMC will also 
make recommendations to the Sponsor protocol team regarding steps to ensure both subject 
safet y and the continued ethical integrity of the trial.
8.0STATISTICAL ANALYSIS PLAN
This section outlines the statistical analy sis strategy  and procedures for the study .  Changes 
to analy ses made after the protocol has been finalized, but prior to unblinding, will be 
documented in a supplemental SAP (sSAP) and referenced in the Clinical Study  Report 
(CSR) for the study .  Post hoc exploratory  anal yses will be clearl y identified in the CSR. 
  04HYHG 
  058TB6
Product:   V114 47
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialStatistical Analysis Plan Summary 8.1
Key elements of the statistical analy sis plan are summarized below; the comprehensive plan 
is provided in Sections 8.2-8.11.
Trial Design Overview A Phase II, Double -Blind, Randomized, Multicenter Trial to Evaluate the 
Safety, Tolerability, and Immunogenicity of V114 Com pared to Prevnar 
13™ in Healthy Infants
Treatm ent Assignment This is a double -blind trial with three vaccination groups.  Subjects will 
be randomized to V114 Lot 1(V114-1 ), V114 Lot 2(V114-2 ), and 
Prevnar 13™ w ith the ratio 1:1:1.  
Analysis Populations 1.Immunogenicity:  Per -protocol (PP).
2.Safety:  All Subjects as Treated (ASaT)
Prim ary Endpoints 1.The proportion of subjects meeting serotype -specific IgG ≥0.35 
µg/mL for the 13serotypes shared with Prevnar 13™ measured by 
the Pn ECL assay at 1 month post -dose 3
2.The serotype -specific IgG GMC forall 15 serotypes included in 
V114 measured by the Pn ECL assay at 1month post -dose 3
Secondary Endpoint The serotype -specific IgG GMC for all 15 serotypes included in V114 
measured by the Pn ECL assay at pre -dose 4 and 1 month post -dose 4.
Statistical Methods for Key 
Immunogenicity AnalysesTo address the prim ary objective #2, a V114 formulation will be 
considered non-inferior to Prevnar 13™ if the lower bound of the two-
sided 95% confidence interval (CI) of the betw een-treatment difference 
(V114 –Prevnar 13™) in the proportion of subjects with PD3 IgG ≥0.35
µg/mL for the 13 serotypes in common between V114 andPrevnar 13™ 
is >-0.15. The Miettinen and Nurminen approach [21] will be used.
To address the prim ary objective #3, the within -group IgG GMC along 
with two-sided 95% CIs will be computed for all 15 serotypes included 
in V114. Additionally, GMC ratios (V114/Prevnar 13™) along with two -
sided 95% CIs will be computed for each of the two V114 lots(V114 -1 
and V114 -2)for all15 serotypes included in V114. The 95% CI for the 
ratio w ill be calculated .
Statistical Methods for Key 
Safety AnalysesThe analysis of safety results will follow a three -tier approach.  The tiers 
differ with respect to the analyses that will be performed.
Tier 1 safety endpoints include solicited injection -site adverse event s 
(redness, hard lump,swelling, and pain/tenderness) and system ic adverse 
event s (irritability, drow siness, hives/welts, appetite loss )during Day 1 to 
Day 14 postvaccination .  For Tier 1 safety endpoints (those adverse 
event s specifically prom pted for on the VRC), point estim ates, risk 
differences with 95% CIs and corresponding p -values will be provided. 
Adverse event s not defined as Tier 1 (specific terms as well as system 
organ class terms) will be classified as belonging to "Tier 2" or "Tier 3".  
Tier 2 parameters (adverse events that occur in at least 4subjects in any 
vaccination group) will be assessed via point estimates and risk 
differences with 95% CIs; only point es timates by group will be provided 
for Tier 3 safety param eters.  In this trial, temperatures collected from 
Day 1 through Day 7 will be treated as Tier 2 events. 
  04HYHG 
  058TB6
Product:   V114 48
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialInterim Analysis An interim analysis of the immunogenicity will be performed in this trial
when ~100% PD3 safety follow -up completed and ~100% PD3 
immunogenicity results (IgG responses) are available . An internal 
statistician , statistical programmer , and clinical scientist not assigned to 
the protocol will be unblinded throughout the duration of the trial to 
perform the interim analysis. Group summaries of the IgG results will be 
reviewed by the project team; however, the project team will not be 
unblinded at the subject level.  The Sponsor’s trial team will use the 
results to make scientific decisions regarding future studies.  It may also 
inform certain scientific consultations.  The Haybittle -Peto rule [18][19]
using 1-sided significance level of α=0.0005 will be utilized to account 
for the interim analysis.  The final analysis will still be evaluated at a 1-
sided significance level of α =0.025.
Multiplicity The type I error for the prim ary immunogenicity analyses will be 
controlled at the one-sided significant level of 0.025 by testing 
hypotheses related to V114 -1and hypotheses related to V114-2
simultaneously using a Hochberg approach [20].  
Sample Size and Power Approximately 1050 subjects will be enrolled, with approximately 350 
subjects in each of the three vaccination groups. There is >90% power to 
declare non-inferiority to Prevnar 13™ for the common serotypes and 
superiority for the non-common serotypes for at least one of the V114 
lots based on the proportion of subjects meeting the serotype -specific 
IgG ≥0.35 µg/mL .This power assume s an 85% evaluability rate (~298 
subjects per group), a non-inferior itymargin of -0.15 in the difference 
(V114 –Prevnar 13™), and a serotype -specific true the response rate 
based on the group level results from the V114 -003 CSR, the V114 -004 
interim analysis and the knowledge of the V114 formulation that will be 
used in this trial. 
Responsibility for Analyses/In -House Blinding 8.2
The statistical analysis of the data obtained from this trial will be the responsibility  of the 
Clinical Bi ostatistics department of the Sponsor.
This trial will be conducted as a double -blind trial without complete in-house blinding 
procedures.  Section 5.2.3 specifies the roles and responsibilities of the site and Sponsor 
personnel who will be unblinded during the trial.  The official, final database will not be 
unblinded until medical/scientific review has been performed, protocol deviations have been 
identified, and data have been declared final and complete. 
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
trial treatment assignment.  Randomization will be implemented using interactive response 
technology  (IRT).
With the exception of the unblinded CRA who will monitor and reconcile the trial vaccine, 
all other MRL  employ ees directly  involved with the conduct of this trial will remain blinded 
to the subject’s treatment assignment until medical/scientific review of all safety  and 
immunogenicit y data has been performed, protocol deviations have been identified, and data 
have been declared final and complete. 
  04HYHG 
  058TB6
Product:   V114 49
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialThe planned interim analysis is described in Section 8.7.  The results of interim analysis will 
not be shared with the investigators prior to the completion of the trial.  Subject -level 
unblinding will be restricted to the internal unblinded statistician and unblinded statistical 
programmer performing the interim analysis.  Group summaries will be reviewed by the
Sponsor’s trialteam in order to make scientific decisions for future studies.
Hypotheses/Estimation 8.3
Objectives and h ypotheses of the trialarestated in Section 3.0.
Analysis Endpoints 8.4
Immunogenicit y and safety  endpoints that will be evaluated for within -and between -
treatment differences are listed below.
Immunogenicity Endpoints 8.4.1
The primary  immunogenicity  endpoints include:
(1)The proportion of subjects with seroty pe-specific IgG ≥0.35 µg/mL measured by the 
Pn ECL  assay at 1 month post-dose 3 for the 13 common serot ypes (1, 3, 4, 5, 6A, 
6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F) between V114 and Prevnar 13™ in 
recipients of either lot of V114 and Prevnar 13™.
(2)The IgG GMCs for the 13 common seroty pes (1, 3, 4, 5, 6A, 6B, 7F,9V, 14, 18C, 
19F, 19A, and 23F) between V114 and Prevnar 13™, and 2 seroty pes unique to V114 
(22F and 33F) in recipients of either lot of V114 and Prevnar 13™, based on the 
seroty pe-specific IgG responses as measured by the Pn ECL  assay at 1 month post-
dose 3.
The secondary  and exploratory  immunogenicity  endpoints include: 
(1)The proportion of subjects with seroty pe-specific IgG ≥0.35 µg/mL measured by the 
Pn ECL assay at 1 month post-dose 3 for the 2 seroty pes unique to V114 (22F and 
33F) in recipients of either lot of V114 and Prevnar 13™.
(2)The IgG GMCs for all 15 pneumococcal serot ypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19F, 19A, 22F, 23F, and 33F) in recipients of either lot of V114 and Prevnar 
13™, based on the seroty pe-specific IgG responses as meas ured by  the Pn ECL  assay 
at pre -dose 4 and 1 month post -dose 4.
(3)The proportion of subjects with seroty pe-specific IgG ≥0.35 µg/mL measured by the 
Pn ECL  assay at pre -dose 4 and 1 month post -dose 4 for the 13 common seroty pes (1, 
3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F) between V114 and Prevnar 
13™ ,and 2 seroty pes unique to V114 (22F and 33F) in recipients of either lot of 
V114 and Prevnar 13™ .
(4)The proportion of subjects with seroty pe-specific OPA titer ≥8 and OPA GMTs as 
measured by the MOPA -4 assay  at 1 month post-dose 3, pre-dose 4, and 1 month 
post-dose 4 for all 15 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F, 
23F and 33F) in recipients of either lot of V114 and Prevnar 13™. 
  04HYHG 
  058TB6
Product:   V114 50
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialSafety Analysis Endpoints 8.4.2
Refer to Section 4.2.3 .2 for the description of the safet y measures in this trial.
Safety  and tolerability  will be assessed by  clinical review of all relevant parameters including 
AEs.  Tier 1 events for this trial consist of the solicited injection -site and solicited systemic 
AEs.
Analysis Populations 8.5
Immunogenicity Analysis Populations 8.5.1
The Per-Protocol (PP) population will serve as the primary  population for the analysis of 
immunogenicit y data in this trial. The PP population consists of those subjects who are not 
considered as protocol violators.  Violations include but are not limited to: failure to receive 
the scheduled doses [at least 28 days between doses 1 and 2 and between doses 2 and 3(for 
PD3, Pre-dose 4, and PD4 PP analy ses), and dose 4 at 12 months to 15 months of age (for 
PD4 PP analyses)] of correct clinical material, and lack of valid serology  results available 
from 28 to 42 days following the dose being analy zed. The final determination on protocol 
violations will be made prior to unblinding of the database and will be documented in a 
separate memo .
The Full Analy sis Set (FAS) population will also be used for supplementary  analysis of the 
primary  analyses.  The FAS population consists of all randomized subjects who received at 
least one vaccination and have at least one serology  result.  Subjects will be included in the 
vaccination group to which they  are randomized for the analys is of immunogenicity data.
Safety Analysis Populations 8.5.2
The ASaT population will be used for the analysis of safety  data in this trial. The ASaT 
population consists of all randomized subjects who received trial vaccine. Subjects will be 
included in the group corresponding to the clinical material they actually  received fo r the 
analysis of safety  data using the ASaT population. For most subjects this will be the group to 
which they are randomized. Subjects who receive incorrect clinical material will be included 
in the group corresponding to the clinical material actuall y received.
Statistical Methods 8.6
For immunogenicit y analy ses, unless otherwise specified, all statistical tests will be 
conducted at the α=0.05 (two-sided) level .  Results that will be considered to be statisticall y 
significant (versus nominally  significant) after consideration of the strategy  for controlling 
type-I errors, are described in Section 8 .8, Multiplicity .
Statistical Methods for Immunogenicity Analyses 8.6.1
The immunogenicit y analy ses will be conducted for each serot ype separately . 
  04HYHG 
  058TB6
Product:   V114 51
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialFor the primary  hypothesis, a V114 lot will be considered non -inferior to Prevnar 13™ if the 
lower bound of the two-sided 95% confidence interval (CI) forthe between -treatment 
difference (V114 -Prevnar 13 ™) in the proportion of subjects meeting seroty pe -specific IgG 
≥0.35 µ g/mL at 1 month post -dose 3 for the 13 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 
19F, 19A and 23F) in common between V114 andPrevnar 13™ is >-0.15 (15 percentage 
point non-inferiority  margin). The proposed 15 percent age point provides adequate precision 
around the primary  immunologic endpoints and greater confidence in predicting the outcome 
of the Phase III pivotal study .The Miettinen and Nurminen approach will be used .
The within -group IgG GMC along with two-sided 95% CIs will be computed for all15 
seroty pes included in V114. Point estimates of GMCs are theexponent iated estimates of the 
mean natural logconcentrations. The confidence limits for GMCs are the exponentiated 
confid
ence limits for the mean natural logconcentra tions, based on 1-sample t - distributions. 
Additionally , GMC ratios (V114/Prevnar 13™) along with two-sided 95% CIs will be 
computed for each of the two V114 lots (V114 -1 and V114 -2)relative to Prevnar 13™ for 
all 15seroty pesincluded in V114 . The 95% CI for the ratio will be calculated using the t-
distribution with the variance estimate derived from a linear model utilizing the log-
transformed antibody  titers as the response and a single term for vaccination group (including 
the subjects from b oth V114 lotsand Prevnar 13™).
A detailed analy sis strategy  for immunogenicity  endpoints is listed in Table 3.
Table 3  
Anal ysis Strategy  for Immunogenicit y Variables
Endpoint /Variable
(Description ,Time Point )Statistical MethodAnalysis
PopulationMissing
Data
Approach
Prim aryObjectives
Proportion of subjects with
PD3 IgG ≥0.35µg/mL for the 
13 common serotypes  
betw een V114 and Prevnar 
13™Non-inferiority of V114 compared 
with Prevnar 13™ , based on 
difference in percentages (Miettinen 
and Nurminen) PP [Primary]
FAS [Supportive]Missing data 
will not be 
imputed
The PD3 IgG GMCs for all 
15 serotypes included in 
V114Within- group GMCs and 95% CI
GMC ratio (V114/Prevnar 13™) 
and 95% CI(t-distribution with 
the variance estimate from a linear 
model including the subjects from 
both V114 lots and Prevnar 13™ )PP [Primary]
FAS [Supportive]Missing data 
will not be 
imputed
Secondary Objectives
The pre-dose 4 and PD4 IgG 
GMCs for all 15serotypes 
included in V114Within- group GMCs and 95% CI
GMC ratio (V114/Prevnar 13™) 
and 95% CI(t-distribution with 
the variance estimate from a 
linear model including the 
subjects from both V114 lotsand 
Prevnar 13™)PPMissing data 
will not be 
imputed
GMC = Geometric Mean Concentration
GMFR = Geometric mean fold rise from Day 1.
PP = Per -protocol
FAS = Full Analysis Set
CI = Confidence interval 
  04HYHG 
  058TB6
Product:   V114 52
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialStatistical Methods for Safety Analyses 8.6.2
Safety  and tolerability  will be assessed by  clinical review of all relevant parameters including 
adverse event s. Comparisons will be made between the V114 lots and Prevnar 13™ 
following each dose, and across all doses as outlined below.
The analysis of saf ety results will follow a tiered approach.  The tiers differ with respect to 
the analyses that will be performed.  For Tier 1 safet y endpoints (those adverse event s 
specificall y prompted on the VRC), point estimates, risk differences with 95% CIs and 
corre sponding p-values will be provided.  Tier 2 parameters will be assessed via point 
estimates and risk differences with 95% CIs. These analyses will be performed using the 
Miettinen and Nurminen method. Only  point estimates by group will be provided for Tier 3 
safet y parameters.
Tier 1 safet y endpoints include solicited injection -site adverse event s (redness, swelling, hard 
lump, and pain/tenderness) during Day 1 to Day 14postvaccination, and solicited systemic 
adverse event s (irritability , drowsiness, hives /welts, appetite loss) during Day 1 to Day 14 
postvaccination.
Adverse event s (specific terms as well as system organ class terms) will be classified as 
belonging to "Tier 2" or "Tier 3", based on the number of events observed.  Membership in 
Tier 2 requir es that at least 4 subjects in any vaccination group exhibit the event; all other 
adverse event s will belong to Tier 3.  In this trial, temperatures collected from Day 1 through 
Day 7 will be treated as Tier 2 events and will be summarized.
The threshold of at least 4 events was chosen because the 95% CI for the between -group 
difference in percent incidence will alway s include zero when vaccination groups of equal 
size each have less than 4 events and thus would add little to the 
interpretation of potential ly 
meaningful differences.  Because many 95% CIs may be provided without adjustment for 
multiplicity , the CIs should be regarded as a helpful descriptive measure to be used in 
review, not a formal method for assessing the statistical significance of the between -group 
differences in adverse events.
For this protocol, the broad clinical adverse event categories consisting of the percentage of 
subjects with any adverse event , a vaccine -related adverse event , with a serious adverse 
event , with an adverse event which is both vaccine -related and serious, and who died or
discontinued due to an adverse event will be considered Tier 2 endpoints. 
  04HYHG 
  058TB6
Product:   V114 53
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialTable 4  Anal ysis Strategy  for Safet y Parameters
Safety 
Tier Safety Endpoint†p-Value95% CI fo r 
Com parisonDescriptive
Statistics
Tier 1Injection -siteredness (Days 1to14) X X X
Injection -site swelling (Days 1to14) X X X
Injection -sitepain ortenderness (Days 1to14) X X X
Injection -site hard lump (Days 1 to 14) X X X
Irritability (Days 1to14) X X X
Drowsiness (Day s 1to14) X X X
Hives/welts (Days 1to14) X X X
Appetite loss (Days 1to14) X X X
Tier 2Any AE X X
Any Serious AE X X
Any Vaccine -Related AE X X
Any Serious and Vaccine -Related AE X X
Discontinuation duetoAE X X
Specific AEs or SOCs‡(incidence ≥4 of subjects 
in one of the vaccination groups)X X
Body temperature (Day 1 to 7) X X
Tier 3Specific AEs or SOCs‡(incidence <4 of subjects 
in all vaccination groups)X
† Adverse event (AE) references refer toboth Clinical andLaboratory AEs.
‡Includes only those endpoints notpre-specified asTier 1 or not already pre-specified asTier-2endpoints.
SOC=System Organ Class
X=results will beprovided.
Summaries of Demographics and Baseline Characteristics 8.6.3
The comparability  of thevaccination groups for each relevant demographic and baseline 
characteristic will be assessed by the use of summary  tables.  No statistical hypothesis tests 
will be performed on these characteristics.  The number and percentage of subjects 
randomized and vaccinated, and the reasons for discontinuation (including subjects 
discontinued for meeting the rescue criterion) , will be display ed by group.  Demographic 
variables (e.g., age), prior and concomitant therapies and vaccines will be summarized by 
group.
Interim Analyses 8.7
An interim analysis of the immunogenicity  will be performed in this trial when ~100% PD3 
safet y follow -up completed and ~100% PD3 immunogenicit y results (IgG responses) are 
available ..  Group summaries of the IgG results will be reviewed; however, the project team 
will not be unblinded at the subject level.  The Sponsor’s trial team will use the results to 
make scientific decisions regarding future studies. The conduct of this trial will n ot be altered 
by theinterim anal ysis. The Hay bittle -Peto rule using 1 -sided significance level of α =0.0005 
will be utilized to account for the interim analy sis.  The final analy sis will still be evaluated 
at a 1 -sided significance level of α =0.025.
The endpoints, timing, and purpose of the interim anal ysis are summarized in Table 5. 
  04HYHG 
  058TB6
Product:   V114 54
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialTable 5  Summary  of Interim Anal ysis Strategy
Key Endpoints for Interim Analysis Timing of Interim  Analysis Purpose of Interim Analysis
Proportion of subjects with PD3 IgG 
≥0.35 µg/mL forall 15 serotypes in 
V114
The PD3 IgG GMCs for all 15 
serotypes included in V114
PD3 percentage of subjects with any 
AE, a vaccine related AE, a serious 
AE, and an AE which is both 
vaccine -related and serious, and who 
died or discontinued due to an AE.~100% PD3 safety follow -up 
completed and ~100% PD3
immunogenicity results (IgG 
responses) are availableInform scientific decisions for 
future studies
Multiplicity 8.8
Non-inferiorit y testswill be conducted for the 13 shared serot ypes between V114 and 
Prevnar 13™ .The overall success for each of the V114 lots requires demonstrating non-
inferior to Prevnar 13™ for each of the13serot ypes. This approach controls the overall type 
I error within each lot, therefore no multiplicity  adjustment will be required within each lot.
The type I error for the primary  immunogenicity analysis will be controlled at the one-sided 
significant level of 0.025 by testing V114 -1 and V114 -2 simultaneously  using a Hochberg 
approach, which is summarized in Figure 2.  
Figure 2  Diagram of the Multiplicity  Adjustment
 
  04HYHG 
  058TB6
Product:   V114 55
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialBoth lotswill first be tested using a 1-sided alpha of 0.025 respectively .  If all tests for both 
lotsare significant (p-value < 0.025) or at least one test for both lotsisnon-significant (p-
value ≥ 0.025) , testing is complete.  However, if one lotissuccessful at the 1-sided alpha of 
0.025 and the other is not, the successful lotwill be re-tested at a more stringent 1-sided 
alpha of 0.0125 (0.025/2). The level of the confidence interval will align with the ty pe I error 
during the re-testing procedure , i.e., the 97.5% CI will be provided if only  one of the two lots 
succeeds. Testing in this manner controls the type I error for the prim ary immunogenicity 
analysis at the 1 -tailed α=0.025.
The Haybittle -Peto rule using 1-sided significance level of α=0.0005 will be utilized to 
account forthe interim analysis.  The final analy sis will still be evaluated at a 1-sided 
significance level of α =0.025 as described in Section 8.7.
No multiplicity  adjustments will be made for the safet y comparisons.
Sample Size and Power Calculations 8.9
Immunogenici ty Analyses 8.9.1
Approximately  1050 subjects will be enrolled, with approximately  350subjects in each of the 
three vaccination groups. For the primary  immunogenicit y hypothes es, the power is 
simulated based on the Hochberg approach. There is >90% power to declare non-inferiority 
to Prevnar 13™ for the 13 common seroty pes between V114 and Prevnar 13™ and 
superiority  for the twoserotypes unique to V114 for at least one of the V114 lotsbased on 
the proportion of subjects meeting the seroty pe-specific IgG ≥0.35 µg/mL .This power 
assumes an 85% evaluability  rate (~298subjects per group), a non -inferior itymargin of -0.15 
for the difference (V114 –Prevnar 13™) , and a seroty pe-specific true percentage of the 
response rate based on the group level results from the V114 -003 CSR, the V114 -004 interim 
analysis and the knowledge of the V114 formulation that will be used in this trial. Based on 
this knowledge, it was conservativel y assume dthat the true response ratesof V114 will be 
0.05 lower than that of Prevnar 13™ f or seroty pes 6A, 6B, and 19A, 0.20 higher for seroty pe 
3, and the same for the remaining serot ypes . The assumption of the true percentage for each 
seroty pe can be found in Table 6.
Note that the overall power is sensitive to the assumed response rate of V114 for the 
seroty pes which are assumed to have lower response rates (6A, 6B, and 19A). For example, 
if the V114 response rate for 6B is decreased from 0.82 to 0.80 (0.07lower than that of 
Prevnar 13™) , the power will be ~80%. 
Further details are provide d in the sSAP. 
  04HYHG 
  058TB6
Product:   V114 56
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialTable 6   
Safety Analyses 8.9.2
For safet y comparisons, all subjects are expected to be evaluable. If no serious adverse event
is observed among the 350 subjects in each vaccination group, this trial provides 97.5% 
confidence that the true serious adverse event rate is <1.05% (1 out of every 95 subjects).
The probability  of observing at least one serious adverse event in this trialdepends on the 
number of subjects enrolled and the incidence rate of serious adverse event s in the general 
population.  I f the incidence rate of a serious adverse event is 1 of every  217 recipients of the 
vaccine (0.46%), then there is an 80% chance of observing at least one such serious adverse 
event among 350 subjects in the vaccine group. If the incidence rate is 1 of every 505 
recipients (0.2%), there is a 50% chance of observing at least one serious adverse event .
For safet y comparisons, risk differ ences between any 2 vaccination groups that could be 
detected with an 80% probability  are summarized in Table 7for a variety  of hy pothetical true 
incidence rates.  These calculations assume there are 350 subjects for safety  in both groups 
and are based ona 2-sided significance level of α =0.05.  No multiplicity  adjustments were 
made in these calculations. 
  04HYHG
CCI
CCI 
  058TB6
Product:   V114 57
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialTable 7  Differences in Incidence of Adverse event Rates between the Two Vaccination 
Group sThat Can be Detected With an ~80% Probability  and a Two -Sided 
Significance Level of 0.05
True Incidence Rate of Adverse 
event s in V114
(%)
N=350True Incidence Rate of Adverse 
event s in Prevnar 13™
(%)
N=350Detectable Percentage Point 
Difference in Incid ence Rates of 
Adverse event s
2.5 0.1 2.4
6.2 2.0 4.2
10.7 5.0 5.7
17.3 10.0 7.3
23.3 15.0 8.3
29.1 20.0 9.1
40.1 30.0 10.1
NOTE: The incidence rates for each vaccination group are hypothetical.
Subgroup Analyses and Effect of Baseline Factors 8.10
The GMC responses as measured by Pn ECL  to all 15 seroty pes contained in V114 will be 
summarized by vaccination group in each country subgroup , in order to assess potential 
differences b y thisfactor.
Extent of Exposure 8.11
The number of subjects vaccinated wil l be summarized by  vaccination group.
9.0LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES
Investigational Product 9.1
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribution and usage of 
investigational product in accordance with the protocol and any applicable laws and 
regulations.
Clinical Supplies will be provided b y the Sponsor as summarized in Table 8.
Table 8  Product Description s
Product Name & 
PotencyDosage Form Source/Additional Information
V114 Lot10.5 mL dose sterile 
suspension for I.M. injectionProvided centrally by the Sponsor 
V114 Lot20.5 mL dose sterile 
suspension for I.M. injectionProvided centrally by the Sponsor 
Prevnar 13 ™0.5 mL dose sterile 
suspension for I.M. injectionProvided centrally by the Sponsor 
  04HYHG 
  058TB6
Product:   V114 58
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialPackaging and Labeling Information 9.2
Clinical supplies will be affixed with a clinical label in accordance with regulator y 
requirements.
Sites will receive open label single dose s yringe kits. Each kit will contain 1syringe . 
Clinical Supplies Disclosure 9.3
This trial is blinded but supplies are provided open label; therefore, an unblinded pharmacist 
or qualified trial site personnel will be used to blind supplies. Vaccine identity  (name, 
strength or potency ) is included in the label text; random code/ disclosure envelopes or lists 
are notprovide d.
The emergency  unblinding call center will use the treatment/ randomization schedule for the 
trial to unblind subjects and to unmask vaccine identity . In the event that the emergency 
unblinding call center is not available for a given site in this trial, the central electronic 
treatment allocation/ randomization system (IVRS/I WRS) should be used in order to unblind 
subjects and to unmask treatment/vaccine identity . The Sponsor will notprovide random 
code/disclosure envelopes or lists with the clinical supplies .
Vaccine identification information is to be unmasked ONLY if necessary for the welfare of 
the subject.  Every  effort should be made not to unblind the subject unless necessary . 
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., 
date, reason and person performing the unblinding ) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible.  Only the principal investigator or 
delegate and the respective subject ’s code should be unblinded.  Trial site personnel and 
Sponsor personnel directly  associated with the conduct of the trial should not be unblinded to 
treatment assignment .Subjects whose treatment assignment has been unblinded (by the 
investigator, Merck subsidiary , or through the emergency  unblinding call center) must be 
discontinued from study  drug , but should continue to be monitored in the trial .
Storage and Handling Requirements 9.4
Clinical supplies must be stored in a secure, limited -access location unde r the storage 
conditions specified on the label.  
Receipt and dispensing of trial medication must be recorded by an authorized person at the 
trial site.
Clinical supplies may  not be used for an y purpose other than that stated in the protocol.
Discard/Dest ruction/ Returns and Reconciliation 9.5
The investigator is responsible for keeping accurate records of the clinical supplies received 
from the Sponsor or designee, the amount dispensed to and returned by the subjects and the 
amount remaining at the conclusion of the trial. For all trial sites, the local country  Sponsor 
personnel or designee will provide appropriate documentation that must be completed for 
drug accountability  and return, or local discard and destruction if appropriate.   Where local 
discard and destruction is appropriate, the investigator is responsible for ensuring that a local 
discard/destruction procedure is documented . 
  04HYHG 
  058TB6
Product:   V114 59
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialStandard Policies 9.6
Trial site personnel will have access to a central electronic treatment 
allocation/ randomization system (IVRS/I WRS system) to allocate subjects, to assign vaccine
to subjects and to manage the distribution of clinical supplies. Each person accessing the 
IVRS system must be assigned an individual unique PIN.  They must use only their assi gned 
PIN to access the sy stem, and they  must not share their assigned PIN with any one.
10.0 ADMINISTRATIVE AND R EGULATORY DETAILS
Confidentiality 10.1
Confidentiality of Data 10.1.1
By signing this protocol, the investigator affirms to the Sponsor that information furnishe d to 
the investigator by the Sponsor will be maintained in confidence, and such information will 
be divulged to the institutional review board, ethics review committee (IRB/ERC) or similar 
or expert committee; affiliated institution and employ ees, only under an appropriate 
understanding of confidentiality  with such board or committee, affiliated institution and 
employ ees.  Data generated by this trial will be considered confidential by the investigator, 
except to the extent that it is included in a publicat ion as provided in the Publications section 
of this protocol.
Confidentiality of Subject Records 10.1.2
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory  authority  representatives may consult and/or copy trial documents in 
order to verify  worksheet/case report form data.  By signing the consent form, the subject 
agrees to this process.  If trial documents will be photocopied during the process of verify ing 
worksheet/case report form information , the subject will be identified by unique code only; 
full names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all subject data used and disclosed in 
connection with this trial in accordance with all applicable privacy laws, rules and 
regulations.
Confidentiality of Investigator Information 10.1.3
By signing this protocol, the investigator recognizes that certain personal identify ing 
information with respect to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory  
submissions, and as required b y law.  This information may include:
1.name, address, telephone number and e -mail address;
2.hospital or clinic address and telephone number;
3.curriculum vitae or other summary  of qualifications and credentials; and
4.other professional documentation. 
  04HYHG 
  058TB6
Product:   V114 60
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialConsistent with the purposes described above, this information may be transmitted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country  and other 
countries, including countries that do not have laws protecting such information.  
Additionally , the investigator’s name and business contact information may be included 
when reporting certain serious adverse events to regulatory  authorities or to other 
investigators.  By signing this protocol, the investigator expressly  consents to these uses and 
disclosures.
If this is a multicenter trial, in order to facilitate contact between investigators, the Sponsor 
may share an investigator’s name and contact information with other participating 
investigators upon request.
Confidentiality of IRB/IEC Information 10.1.4
The Sponsor is required to record the name and address of each IRB/IEC that revie ws and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements by requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records availab le for 
regulatory  agency  review upon request b y those agencies.
Compliance with Financial Disclosure Requirements 10.2
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by Clinical Investigat ors (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such reque st.  
The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certificatio n and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by 
the Sponsor . The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance with Law, Audit and Debarment 10.3
By signing this protocol, the investigator agrees to conduct the trial in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of Good 
Clinical Practice (e.g., International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guideline and other generally  accepted standards of good clinical practice); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by  Merck, is provided in Section 12.1 -
Merck Code of Conduct for Clinical Trials . 
  04HYHG 
  058TB6
Product:   V114 61
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialThe investigator also agrees to allow monitoring, audits, IRB/ERC review and regulatory  
authority  inspection of trial-related documents and procedures and provide for direct access 
to all trial-related source data and documents.
The in vestigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator b y the Sponsor.
The investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or terminat ion of the clinical trial, submit any other reports to the 
Sponsor as required by  this protocol or as otherwise required pursuant to any  agreement with 
the Sponsor.
Trial documentation will be promptly  and fully disclosed to the Sponsor by the investigator
upon request and also shall be made available at the trial site upon request for inspection, 
copy ing, review and audit at reasonable times by representatives of the Sponsor or any 
regulatory  authorities.  The investigator agrees to promptly  take any  reasonable steps that are 
requested b y the Sponsor as a result of an audit to cure deficiencies in the trial documentation 
and worksheets/case report forms.
The investigator must maintain copies of all documentation and records relating to the 
conduct of the tr ial in compliance with all applicable legal and regulatory  requirements.  This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory  authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory  reference ranges, laboratory  certification or 
quality  control procedures and laboratory  director curriculum vitae.  By  sign ing this protocol, 
the investigator agrees that documentation shall be retained until at least 2 years after the last 
approval of a marketing application in an ICH region or until there are no pending or 
contemplated marketing applications in an ICH region or until at least 2 years have elapsed 
since the formal discontinuation of clinical development of the investigational product.  
Because the clinical development and marketing application process is variable, it is 
anticipated that the retention period can be up to 15 years or longer after protocol database 
lock. The Sponsor will determine the minimum retention period and notify  the investigator 
when documents may be destro yed.  The Sponsor will determine the minimum retention 
period and upon request, will provide guidance to the investigator when documents no longer 
need to be retained.  The sponsor also recognizes that documents may  need to be retained for 
a longer period if required by local regulatory  requirements. All trial documents shall be 
made available if required by relevant regulatory  authorities. The investigator must consult 
with and obtain written approval b y the Sponsor prior to destro ying trial and/or subject files.  
ICH Good Clinical Practice 
guidelines recommend that the investigator inform the subject’s 
primary  physician about the subject’s participation in the trial if the subject has a primary  
physician and if the subject agrees to the primary  physician being informed.
The investigator will promptly  inform the Sponsor of any regulatory  authority  inspection 
conducted for this trial. 
  04HYHG 
  058TB6
Product:   V114 62
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialPersons debarred from conducting or working on clinical trials by any court or regulatory 
authority  will not be allowed to conduct or work on this Sponsor’s trials.  The investigator 
will immediately  disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
In the event the Sponsor prematurel y terminates a particular trial site, the Sponsor will 
promptly  notify  that trial site’s I RB/IEC.
According to European legislation, a Sponsor must designate an overall coordinating 
investigator for a multi -center trial (including multinational).  When more than one trial site 
is open in an EU country, Merck, as the Sponsor, will designate, per country , a national 
principal coordinator (Protocol CI), responsible for coordinating the work of the principal 
investigators at the different trial sites in that Member State, according to national 
regulations.  For a single -center trial, the Protocol CI is the principal investigator.  In 
addition, the Sponsor must designate a principal or coordinating investigator to review the 
trial report that summarizes the trial results and confirm that, to the best of his/her 
knowledge, the report accuratel y describes the conduct and results of the trial [Clinical Study  
Report (CSR) CI].  The Sponsor may consider one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availability  of the CI during the 
anticipated review process, thorough understanding of clinical trial methods, appropriate 
enrollment of subject cohort, timely  achievement of trial milestones).  The Protocol CI must 
be a participati ng trial investigator.
Compliance with Trial Registration and Results Posting Requirements 10.4
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency  (EMA) clinical trial Directive 2001/20/EC, the S ponsor 
of the trial is solely  responsible for determining whether the trial and its results are subject to 
the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries.  Merck, as Sponsor of this trial, will 
review this protocol and submit the information necessary  to fulfill these requirements. 
Merck entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.  
Information posted will allow subjects to identify  potentiall y appropriate trials for their 
disease conditions and pursue participation by calling a central contact number for further 
information on appropriate trial locations and trial site contact information.  
By signing this protocol, the investigator acknowled ges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locall y mandated registries are that of the 
Sponsor and agrees not to submit any information about this trial or its results to those 
registries. 
  04HYHG 
  058TB6
Product:   V114 63
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialQuality Managemen t System 10.5
By signing this protocol, the Sponsor agrees to be responsible for implementing and 
maintaining a quality  management system with written development procedures and 
functional area standard operating procedures (SOPs) to ensure that trials are cond ucted and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and 
regulations relating to the conduct of the clinical trial.
Data Management 10.6
The investigator or qualified designee is responsible for recording and verify ing the accuracy 
of subject data.  By signing this protocol, the investigator acknowledges that his/her 
electronic signature is the legall y binding equivalent of a written signature.  By enterin g 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
Publicat ions 10.7
This trial is intended for publication, even if terminated prematurel y. Publication may include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within 12 months after the last data 
become available, which may take up to several months after the last subject visit in some 
cases such as vaccine trials.  However, manuscript submission timelines may  be extended on 
OTC trials.  For trials intended for pediatric -related regulatory  filings, the investigator agrees 
to delay  publication of the trial results until the Sponsor notifies the investigator that all 
relevant regulatory  authority  decisions on the trial drug have been made with regard to 
pediatric -related regulatory  filings. Merck will post a synopsis of trial results for approved 
products on www.clinicaltrials.gov by 12 months after the last subject's last visit fo r the 
primary  outcome, 12 months after the decision to discontinue development, or product 
marketing (dispensed, administered, delivered or promoted), whichever is later.
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, to protect intellectual property , or to compl y with confidentiality 
agreements with other parties.  Authors of the primary  results manuscript will be provided 
the complete results from the Clinical Study  Report, subject to the confidentiality  agreement. 
When a manuscript is submitted to a biomedical journal, the Sponsor's policy  is to also 
include the protocol and statistical analy sis plan to facilitate the peer and editorial review of 
the manuscript.  If the manuscript is subsequently accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its website the key sections of the protocol that 
are relevant to evaluating the trial, specifically  those sections describing the trial objectives 
and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, 
the efficacy  and safet y measures, the statistical analy sis plan, and any  amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary inf ormation. 
  04HYHG 
  058TB6
Product:   V114 64
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialFor multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrials.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independentl y.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  In rare cases, publication of single trial site data prior to the main 
paper may be of value.  Limitations of single trial site observations in a multicenter trial 
should alway s be described in such a manuscript.
Authorship credit should be based on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpret ation of data; 2) drafting the article or revising 
it critically  for important intellectual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, 2 and 3.  Significant contributions to trial 
execution may also be taken into account to determine authorship, provided that 
contributions have also been made to all three of the preceding authorship criteria.  Although 
publication planning may  begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made based on participation and actual contributions to 
the trial and writing, as discussed above. The first author is responsible for defending the 
integrit y of the data, method(s) of data anal ysis and the scientific content of the manuscript.
The Sponsor must have the opportunity  to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45days prior to submission for publication/presentation. 
Any information identified by the Sponsor as confidential must be deleted prior to 
submission; this confidentiality  does not include efficacy  and safety  results. Sponsor review 
can be expedited to mee t publication timelines. 
  04HYHG 
  058TB6
Product:   V114 65
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential11.0 LIST OF REFERENCES
1.Hicks LA, Harrison, LH, Flannery  B, et al. Incidence of pneumococcal disease due to 
non-pneumococcal conjugate vaccine (PCV7) seroty pes in the United States during the 
era of widespread PCV7 vaccination, 1998 -
2004. JI D 2007, 196: 1346 -54.
2.World Health Organization. WHO Position paper. Wkly  Epidemiol Rec 2007;82(12):93 -
104
3.O’Brien KL, Wolfson LJ, Watt JP, et al, Burden of disease caused by Streptococcus 
pneumoniae in children younger than 5 years: global estimat es. Lancet 2009;374:893 -
902.  
4.WHO 2015 Estimates of disease burden and cost- effectiveness. 
http//who.int/immunization/monitoring_surveillance/burden/estimates/
5.Klugman KP, Cutts F, Adegbola RA, Meta -analy sis of the efficacy of conjugate 
vaccines against invasive pneumococcal disease. In: Siber GR, Klugman KP, Mäkelä 
PH, editors. Pneumococcal vaccines: the impact of conjugate vaccine. ASM Press; 
Washington, DC, USA: 2008
6.Taylor S, Marchisio P, Vergison A, et al. Impact of pneumococcal conjugate vaccination
on otitis media: a sy stematic review. Clin Infect Dis 2012;54(12):1765 -73
7.Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the 
seven -valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012;31(5):501 -8
8.Feikin DR, Kagucia EW, Loo JD, et al. Seroty pe-specific changes in invasive 
pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled 
analysis of multiple surveillance sites. PL oS Med 2013;10(9):e1001517
9.Pilishvili T, Lexau C, Farley  MM, et al. Sustain ed Reductions in I nvasive Pneumococcal 
Disease in the Era of Conjugate Vaccine . J Infect Dis 2010, 201(1): 32 -41
10.Ray GT. Pneumococcal conjugate vaccine: review of cost–effectiveness studies in 
Australia, North America and Europe. Expert Review of Pharmacoeconomics & 
Outcomes Research  2008; 8(4): 373
-93
11.Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in 
children 5 years after conjugate vaccine introduction –eight states, 1998- 2005. MMWR 
Morb Mortal Wkly
 Rep. 2008;57 (6):144-148.
12.Kaplan SL, Barson WJ, Lin PL,  et al.  Serotype 19A is the most common seroty pe 
causing invasive pneumococcal infections in children.  Pediatrics. 2010;125(3):429 -436
13.Pelton SI, Huot H, Finkelstein JA,  et al.  Emergence of 19A as virulent andmultidrug 
resistant Pneumococcus in Massachusetts following universal immunization of infants 
with pneumococcal conjugate vaccine.  Pediatr Infect Dis J. 2007;26(6):468-472
14.Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Seroty pe distribution of 
Streptococcus pneumoniae infections among preschool children in the United States, 
1978- 1994: implications for development of a conjugate vaccine. J Infect Dis. 1995 
Apr;171(4):885
-9. 
  04HYHG 
  058TB6
Product:   V114 66
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential15.Moore MR, Link -Gelles, R, Schaffner,W et al.  Effectiveness of 13-valent
pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in 
children in the USA: a matched case-control study. The Lancet Respiratory Medicine In 
Press. Available online 14 March 2016
16.World Health Organization.  WHO Expert 
Committee on Biological Standardization: 
fifty-fourth report. WHO technical report series, 927; Geneva 2005.
17.World Health Organization. WHO/Health Canada Consultation on Serological Criteria 
for Evaluation and Licensing of New Pneumococcal Vaccines.  2008 Jul 7-8. O ttawa, 
Canada, 2008:1 -
39
18.Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. The 
British Journal of R adiology  1971; 44(526):793 -7.
19.Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and 
analysis of randomized clinical trials requiring prolonged observation of each patient. I. 
Introduction and design. Br J Cancer 1976 Dec; 34(6):585-612.
20.Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. 
Biometrika 1988; 75(4):800-2.
21.Miettine n O, Nurminen M. Comparative Anal ysis of Two Rates. Stat Med 1985; 4:213 -
26. 
  04HYHG 
  058TB6
Product:   V114 67
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential12.0 APPENDICES
Merck Code of Conduct for Clinical Trials 12.1
Merck *
Code of Conduct for Clinical Trials
I. Introduction
A. Purpose
Merck, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, Merck clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by Merck irrespective of the 
party (parties) employed for their execution (e. g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trials which are n ot under the control of Merck.
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of Merck or comparator products.  Alternatively, Merck may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subjects must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
Merck selects investigative sites based on medical expertise, access to appropriate subjects, adequacy of facilities 
and staff, previous performance in Merck trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by Merck personnel to assess the ability to successfully conduct the trial.
3.Site Monit oring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  Merck reviews clinical data for accuracy, completeness and c onsistency. Data are verified versus source 
documentation according to standard operating procedures.  Per Merck policies and procedures, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the respons ible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, Merck seeks to publish the results of trials it conducts.  Some early phase or 
pilot trials are intended to be hypothesis -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues 
of multiplicity.
Merck’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpretation of the analys is, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  Merck funding of a trial will be acknowledged in publications.  
  04HYHG 
  058TB6
Product:   V114 68
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialIII. Subject Protection
A.IRB/ERC review
All clinical trials will be reviewed and approved by an independent IRB/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by the IRB/ERC prior to implementation, except that 
changes required urgentl y to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and Merck will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are ne ver denied access to appropriate medical care 
based on participation in a Merck clinical trial. 
All participation in Merck clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a Merck trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
Merck is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by law, 
only the investigator, sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by name.  
D.Genomic Research
Genomic Research will only beconducted in accordance with informed consent and/or as specifically authorized by 
an Ethics Committee.
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time- and labor-intensive.  It is Merck’s policy to compensate investigat ors (or the sponsoring 
institution) in a fair manner for the work performed in support of Merck trials.   Merck does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, additional payments may be made
to compensate for the time spent in extra recruiting efforts.
Merck does not pay for subject referrals.  However, Merck may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects.
B.Clinical Research Fund ing 
Informed consent forms will disclose that the trial is sponsored by Merck, and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wording of thedisclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from Merck trials will indicate Merck as a source of funding.
C.Funding for Travel and Other Requests
Funding of travel by investi gators and support staff (e.g.,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by the American Medical 
Association (AMA). 
V. Investigator Commit ment
Investigators will be expected to review Merck’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "Merck" refers to Merck Sharp & Dohme Corp. andSchering Corporation, each of which is a 
subsidiary of Merck & Co., Inc.  Merck is known as MSD outside of the United States and Canada.  As warranted by 
context, Merck also includes affiliates and subsidiaries of Merck & Co., Inc." 
  04HYHG 
  058TB6
Product:   V114 69
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialCollection and Management of Specimens for Future Biomedical Research 12.2
1.Definitions
a.Biomarker:  A biological molecule found in blood, other body  fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease.  A biomarker may be 
used t o see how well the body  responds to a treatment for a disease or condition.1
b.Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics as 
related to drug /vaccine response.2
c.Pharmacogenetics:  A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug /vaccine response.2
d.DNA:  Deox yribonucleic acid.
e.RNA:  Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this trial as outlined in Section 7.1.3.3 –
Future Biomedical Research Sample swill be used in various experiments to understand:
oThe biology  of how drugs/vaccines work
oBiomarkers responsible for how a drug/vaccine enters and is removed b y the body
oOther pathway s drugs/vac cines may  interact with
oThe biology  of disease
The specimen(s) may be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from study ing and testing clinical 
specimens offers unique opport unities to enhance our understanding of how individuals 
respond to drugs /vaccines , enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need.  All specimens will be used by the Sponsor or those working for 
or with the Sponsor .
3.Summary of Procedures for Future Biomedical Research
a.Subjects for Enrollment
All subjects enrolled in the clinical trial will be considered for enrollment in the 
Future Biomedical Research sub -trial.
b.Informed Consent
Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all subjects or legal guardians, at a trial 
visit by the investigator or his orher designate.  Informed consent for Future 
Biomedical Research should be presented to the subjects on the visit designated in the 
trial flow chart .  If delayed, present consent at next possible Subject Visit.   Consent 
forms signed by the subject will be kept at the clinical trial site under secure storage 
for regulatory  reasons.   
  04HYHG 
  058TB6
Product:   V114 70
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialA template of each trial site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository .
c.eCRF Documentation for Future Biomedical Research Spec imens
Documentation of subject consent for Future Biomedical Research will be captured in 
the electronic Case Report Forms (eCRFs). Any specimens for which such an 
informed consent cannot be verified will be destroy ed.
d.Future Biomedical Research Specime n(s)
Collection of specimens for Future Biomedical Research will be performed as 
outlined in the trial flow chart. In general, if additional blood specimens are being 
collected for Future Biomedical Research, these will usually  be obtained at a time 
when the subject is having blood drawn for other trial purposes.
4. C onfidential Subject Information for Future Biomedical Research 
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link subjec t' clinical information with future test results. In fact 
little or no research can be conducted without connecting the clinical trial data to the 
specimen. The clinical data allow specific analy ses to be conducted. Knowing subject 
characteristics like gender, age, medical history  and treatment outcomes are critical to 
understanding clinical context of analy tical results.
To maintain privacy  of information collected from specimens obtained for Future 
Biomedical Research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below . 
At the clinical trial site, unique codes will be placed on the Future Biomedical Research 
specimens.  This code is a random number which does not contain any personall y 
identify ing information embedded within it. The link (or key) between subject identifiers 
and this unique code will be held at the trial site.  No personal identifiers will appear on 
the specimen tube.  
5.Biorepository Specimen Usage
Specim ens obtained for the Sponsor will be used for analyses using good scientific 
practices.  Anal yses utilizing the Future Biomedical Research specimens may be 
performed by the Sponsor , or an additional third party (e.g., a university  investigator) 
designated by the Sponsor . The investigator conducting the analy sis will follow the 
Sponsor’s privacy  and confidentiality  requirements. Any contracted third party  analyses 
will conform to the specific scope of anal ysis outlined in this sub- trial. Future Biomedical 
Research specimens remaining with the third party  after specific analy sis is performed 
will be reported to the Sponsor .
6. Withdrawal From Future Biomedical Research 
Subjects may withdraw their consent for Future Biomedical Research and ask that their 
biospecimens not be used for Future Biomedical Research.   Subjects may withdraw 
consent at any time by contacting the principal investigator for the main trial. If medical 
records for the main trial are still available, the investigator will contact the Sponsor
using the designated mailbox (clinical.specimen.management@merck.com).  
  04HYHG 
  058TB6
Product:   V114 71
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialSubsequently , the subject's specimens will be flagged in the biorepository and restricted 
to main study  use only. If specimens were collected from study  participants specificall y 
for Future Biomedical Research, these specimens will be removed from the biorepository  
and destro yed. Documentation will be sent to the investigat or confirming withdrawal 
and/or destruction, if applicable. It is the responsibility  of the investigator to inform the 
subject of completion of the withdrawal and/or destruction, if applicable.  Any analyses 
in progress at the time of request for withdrawal/destruction or already  performed prior to 
the request being received by the Sponsor will continue to be used as part of the overall 
research trial data and results. No new analy ses would be generated after the request is 
received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by regulatory  authorities to retain the main trial 
records) or the specimens have been completel y anony mized, there will no longer be a 
link between the subject’s personal information and their specimens. In this situation, the 
request for withdrawal of consent an d/or destruction cannot be processed.
7. Retention of Specimens 
Future Biomedical Research specimens will be stored in the biorepository  for potential 
analysis for up to 20 years from the end of the main study . Specimens may be stored for 
longer if a regulatory  or governmental authority  has active questions that are being  
answered. In this special circumstance, specimens will be stored until these questions 
have been adequatel y addressed.
Specimens from the trial site will be shipped to a central laboratory  and then shipped to 
the Sponsor -designated biorepository . If a central laboratory  is not utilized in a particular 
trial, the trial site will ship directly  to the Sponsor -designated biore pository . The 
specimens will be stored under strict supervision in a limited access facility  which 
operates to assure the integrity  of the specimens.  Specimens will be destroy ed according 
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository  database.
8.Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated trial administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.
Reporting of Future Biomedical Research Data to Subjects
No inform ation obtained from exploratory  laboratory  studies will be reported to the 
subject, family , or physicians. Principle reasons not to inform or return results to the 
subject include: Lack of relevance to subject health, limitations of predictive capability , 
and concerns regarding misinterpretation. 
  04HYHG 
  058TB6
Product:   V114 72
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialIf important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly  report this information todoctors and subjects.  Subjects will not be identified by 
name in any published reports about this study  or in any other scientific publication or 
presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all subje cts diagnosed and treated on Sponsor clinical 
trials for Future Biomedical Research .
11.Risks Versus Benefits of Future Biomedical Research 
For future biomedical research, risks to the subject have been minimized. Buccal swab 
specimens will be collected inside the cheek with no associated venipuncture to obtain 
the specimen. Therefore, there will not be an additional risk for the subject.
The Sponsor has developed strict security, policies and procedures to address subject data 
privacy  concerns.  Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality .  In this highly unlikely  situation there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to thefuture biomedical research should be e
-mailed directl y to 
clinical.specimen.management@merck.com.
13.References
1.
National Cancer Institute: http://www.cancer.gov/dictionary /?searchTxt=biomarker
2.International Conference on Harmonization: DEFIN ITIO NS FOR GENOMIC 
BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC 
DATA AND SAMPL E CODING CATEGORIES - E15; 
http://www.ich.org/LOB/media/MEDIA3383.pdf
3.Industry  Pharmacogenomics Working Group. Understanding the Intent, Scope and 
Public Health Benefits of Exploratory  Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/
4.Industry  Pharmacogenomics Working Group. Pharmacogenomics Informational 
Brochure for IRBs/IECs and Investigational Site Staff. Availab le at http://i -pwg.org/ 
  04HYHG 
  058TB6
Product:   V114 73
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialApproximate Blood/Tissue Volumes Drawn/Collected by Trial Visit and by 12.3
Sample Types
Trial Visit: Visit 4 Visit 5 Visit 6
Blood Parameter Approximate Blood Volume (mL)
ECL/OPA Assay 5 mL 5 mL 5 mL
Expected Total (mL) 5 mL 5 mL 5mL 
  04HYHG 
  058TB6
Product:   V114 74
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialList of Abbreviations 12.4
AEs Adverse Events
AOM Acute Otitis Media
ASaT All subjects as treated
CAP Community Acquired Pneumonia
CDC Centers for Disease Control and Prevention 
CIs Confidence Intervals
CP Cell wall polysaccharide
CRA Clinical Research Associate
CRU Clinical Research Unit
CSR Clinical Study Report
DEG Data Entry Guideline 
eCRF Electronic Case Report Form
eDMC external Data Monitoring Committee 
EMA European Medicines Agency
EOC Executive Oversight Committee
ERC Ethics Review Committee
EU European Union
FAS Full Analysis Set
FBR Future Biomedical Research
FDAAA Food and Drug Administration Amendments Act
GCPs Good Clinical Practices
GMCs Geometric Mean Concentrations
GMTs Geometric Mean Titers
HEENT Head, Eyes, Ears, Nose and Throat
HIV Human Immunodeficiency Virus
IB Investigator’s Brochure
ICF Informed Consent Form
ICH Institute of Child Health
IGG Immunoglobulin G
IPD Invasive Pneumococcal Disease
IRB Institutional Review Board
IRT interactive response technology
IVRS Interactive Voice Response System
IWRS Integrated Web Response System
MOPA -4 Multiplexed OPA Assay
MRL Merck Research Laboratories
MSD Meso -Scale Discovery
NTHi Non-Typeable Haemophilus influenzae
OPA Opsonophagocytic Killing Activity
PCV Pneumococcal Conjugate Vaccine
PD1 Postdose 1
PD3 Postdose 3
PD4 Postdose 4
Pn ECL Pneumococcal Electrochemiluminescence
PnPs Pneumococcal Polysaccharides
PP Per-protocol
PRO Patient Reported Outcome] 
  04HYHG 
  058TB6
Product:   V114 75
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
ConfidentialSAE Serious Adverse Event/Experience
SOC System Organ Class
SOPs Standard Operating Procedures
sSAP supplemental Statistical Analysis Plan
UAB
US United States
VRC Vaccination Report Card
WHO World Health Organization 
  04HYHG
PPD 
  058TB6
Product:   V114 76
Protocol/Amendment No.: 008-01 
V114 -008-01 Final Protocol 15-Sep-2016
Confidential13.0 SIGNATURES
Sponsor's Representative 13.1
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED
Investigator 13.2
I agree to conduct this clinical trial in accordance with the design outlined in this protocol 
and to abide by all provisions of this protocol (including other manuals and documents 
referenced from this protocol).  I  agree to conduct the trial in accordance with generally 
accepted standards of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particular, I agree to report any serious adverse events 
as defined in Section 7.0–TRIAL PROCEDURES (Assessing and Recording Adverse 
Events ).  I also agree to handle all clinical supplies provided by the Sponsor and collect and 
handle all clinica l specimens in accordance with the protocol.  I understand that information 
that identifies me will be used and disclosed as described in the protocol, and that such 
information may be transferred to countries that do not have laws protecting such 
informat ion.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to any third parties, other than those 
involved in approval, supervision, or conduct of the trial is prohibited.  I will ensure that the 
necessary  precautions are taken to protect such information from loss, inadvertent disclosure 
or access b y third parties.
TYPED NAME
TITLE
SIGNATURE
DATE SIGNED 
  04HYHG 
  058TB6